0001114448 2026-04-01 2026-06-30 0001114448 2025-04-01 2025-06-30 0001114448 2026-01-01 2026-06-30 0001114448 2025-01-01 2025-06-30 0001114448 2026-06-30 0001114448 2025-12-31 0001114448 ifrs-full:IssuedCapitalMember 2026-03-31 0001114448 ifrs-full:TreasurySharesMember 2026-03-31 0001114448 ifrs-full:RetainedEarningsMember 2026-03-31 0001114448 nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember 2026-03-31 0001114448 ifrs-full:EquityAttributableToOwnersOfParentMember 2026-03-31 0001114448 ifrs-full:NoncontrollingInterestsMember 2026-03-31 0001114448 2026-03-31 0001114448 ifrs-full:RetainedEarningsMember 2026-04-01 2026-06-30 0001114448 ifrs-full:EquityAttributableToOwnersOfParentMember 2026-04-01 2026-06-30 0001114448 ifrs-full:NoncontrollingInterestsMember 2026-04-01 2026-06-30 0001114448 nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember 2026-04-01 2026-06-30 0001114448 ifrs-full:TreasurySharesMember 2026-04-01 2026-06-30 0001114448 ifrs-full:IssuedCapitalMember 2026-06-30 0001114448 ifrs-full:TreasurySharesMember 2026-06-30 0001114448 ifrs-full:RetainedEarningsMember 2026-06-30 0001114448 nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember 2026-06-30 0001114448 ifrs-full:EquityAttributableToOwnersOfParentMember 2026-06-30 0001114448 ifrs-full:NoncontrollingInterestsMember 2026-06-30 0001114448 ifrs-full:IssuedCapitalMember 2025-03-31 0001114448 ifrs-full:TreasurySharesMember 2025-03-31 0001114448 ifrs-full:RetainedEarningsMember 2025-03-31 0001114448 nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember 2025-03-31 0001114448 ifrs-full:EquityAttributableToOwnersOfParentMember 2025-03-31 0001114448 ifrs-full:NoncontrollingInterestsMember 2025-03-31 0001114448 2025-03-31 0001114448 ifrs-full:RetainedEarningsMember 2025-04-01 2025-06-30 0001114448 ifrs-full:EquityAttributableToOwnersOfParentMember 2025-04-01 2025-06-30 0001114448 ifrs-full:NoncontrollingInterestsMember 2025-04-01 2025-06-30 0001114448 nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember 2025-04-01 2025-06-30 0001114448 ifrs-full:TreasurySharesMember 2025-04-01 2025-06-30 0001114448 ifrs-full:IssuedCapitalMember 2025-06-30 0001114448 ifrs-full:TreasurySharesMember 2025-06-30 0001114448 ifrs-full:RetainedEarningsMember 2025-06-30 0001114448 nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember 2025-06-30 0001114448 ifrs-full:EquityAttributableToOwnersOfParentMember 2025-06-30 0001114448 ifrs-full:NoncontrollingInterestsMember 2025-06-30 0001114448 2025-06-30 0001114448 ifrs-full:IssuedCapitalMember 2025-12-31 0001114448 ifrs-full:TreasurySharesMember 2025-12-31 0001114448 ifrs-full:RetainedEarningsMember 2025-12-31 0001114448 nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember 2025-12-31 0001114448 ifrs-full:EquityAttributableToOwnersOfParentMember 2025-12-31 0001114448 ifrs-full:NoncontrollingInterestsMember 2025-12-31 0001114448 ifrs-full:RetainedEarningsMember 2026-01-01 2026-06-30 0001114448 ifrs-full:EquityAttributableToOwnersOfParentMember 2026-01-01 2026-06-30 0001114448 ifrs-full:NoncontrollingInterestsMember 2026-01-01 2026-06-30 0001114448 nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember 2026-01-01 2026-06-30 0001114448 ifrs-full:TreasurySharesMember 2026-01-01 2026-06-30 0001114448 ifrs-full:IssuedCapitalMember 2026-01-01 2026-06-30 0001114448 ifrs-full:IssuedCapitalMember 2024-12-31 0001114448 ifrs-full:TreasurySharesMember 2024-12-31 0001114448 ifrs-full:RetainedEarningsMember 2024-12-31 0001114448 nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember 2024-12-31 0001114448 ifrs-full:EquityAttributableToOwnersOfParentMember 2024-12-31 0001114448 ifrs-full:NoncontrollingInterestsMember 2024-12-31 0001114448 2024-12-31 0001114448 ifrs-full:RetainedEarningsMember 2025-01-01 2025-06-30 0001114448 ifrs-full:EquityAttributableToOwnersOfParentMember 2025-01-01 2025-06-30 0001114448 ifrs-full:NoncontrollingInterestsMember 2025-01-01 2025-06-30 0001114448 nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember 2025-01-01 2025-06-30 0001114448 ifrs-full:TreasurySharesMember 2025-01-01 2025-06-30 0001114448 ifrs-full:IssuedCapitalMember 2025-01-01 2025-06-30 0001114448 nvs:AvidityBiosciencesIncMember 2026-02-27 0001114448 nvs:AvidityBiosciencesIncMember 2026-02-27 2026-02-27 0001114448 nvs:AvidityBiosciencesIncMember nvs:AcquiredResearchAndDevelopmentMember 2026-02-27 0001114448 nvs:DM1Member nvs:AvidityBiosciencesIncMember nvs:AcquiredResearchAndDevelopmentMember 2026-02-27 0001114448 nvs:ExcellergyInc.Member 2026-06-24 2026-06-24 0001114448 nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDateMember nvs:ExcellergyInc.Member 2026-06-24 0001114448 nvs:CashAcquiredMember nvs:ExcellergyInc.Member 2026-06-24 0001114448 nvs:PikavationTherapeuticsInc.Member 2026-05-28 2026-05-28 0001114448 nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDateMember nvs:PikavationTherapeuticsInc.Member 2026-05-28 0001114448 nvs:TourmalineBioInc.Member 2025-09-29 0001114448 nvs:TourmalineBioInc.Member 2025-10-28 2025-10-28 0001114448 nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDateMember nvs:TourmalineBioInc.Member 2025-10-28 0001114448 nvs:TourmalineBioInc.Member 2025-10-28 0001114448 nvs:PrivateClinicalStageBiotechCompanyMember 2025-09-16 2025-09-16 0001114448 nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDateMember nvs:PrivateClinicalStageBiotechCompanyMember 2025-09-16 0001114448 nvs:PrivateClinicalStageBiotechCompanyMember 2025-09-16 0001114448 nvs:RegulusTherapeuticsInc.Member 2025-05-27 0001114448 nvs:RegulusTherapeuticsInc.Member 2025-06-24 2025-06-24 0001114448 nvs:RegulusTherapeuticsInc.Member 2025-06-24 0001114448 nvs:RegulusTherapeuticsInc.Member 2025-07-11 0001114448 nvs:RegulusTherapeuticsInc.Member 2025-06-25 2025-06-25 0001114448 nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDateMember nvs:RegulusTherapeuticsInc.Member 2025-06-25 0001114448 nvs:RegulusTherapeuticsInc.Member 2025-06-25 0001114448 nvs:AnthosTherapeuticsInc.Member 2025-04-03 2025-04-03 0001114448 nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDateMember nvs:AnthosTherapeuticsInc.Member 2025-04-03 0001114448 nvs:AnthosTherapeuticsInc.Member 2025-04-03 0001114448 nvs:CashAcquiredMember 2026-06-30 0001114448 2023-07-01 2023-07-31 0001114448 2024-06-01 2024-06-30 0001114448 2025-06-01 2025-06-30 0001114448 2025-07-01 2025-07-31 0001114448 2026-01-01 2026-03-31 0001114448 2026-05-01 2026-05-31 0001114448 nvs:CashAndCashEquivalents1Member nvs:AvailableforsaleFinancialInvestmentsMember ifrs-full:Level1OfFairValueHierarchyMember 2026-06-30 0001114448 nvs:CashAndCashEquivalents1Member nvs:AvailableforsaleFinancialInvestmentsMember 2026-06-30 0001114448 nvs:TotalMarketableSecuritiesAndDerivativeFinancialInstrumentsGroupMember ifrs-full:Level2OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:TotalMarketableSecuritiesAndDerivativeFinancialInstrumentsGroupMember ifrs-full:Level2OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:TotalMarketableSecuritiesAndDerivativeFinancialInstrumentsGroupMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:TotalMarketableSecuritiesAndDerivativeFinancialInstrumentsGroupMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:ContingentConsiderationReceivablesMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:ContingentConsiderationReceivablesMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:ContingentConsiderationReceivablesMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:ContingentConsiderationReceivablesMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:EquitySecuritiesCurrentMember ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:EquitySecuritiesCurrentMember ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:EquitySecuritiesCurrentMember ifrs-full:Level2OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:EquitySecuritiesCurrentMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:EquitySecuritiesCurrentMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:EquitySecuritiesCurrentMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:EquitySecuritiesCurrentMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:AvailableforsaleFinancialInvestmentsMember ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:AvailableforsaleFinancialInvestmentsMember ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:AvailableforsaleFinancialInvestmentsMember ifrs-full:Level2OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:AvailableforsaleFinancialInvestmentsMember ifrs-full:Level2OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:AvailableforsaleFinancialInvestmentsMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:AvailableforsaleFinancialInvestmentsMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:AvailableforsaleFinancialInvestmentsMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:AvailableforsaleFinancialInvestmentsMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:LongTermFinancialInvestmentsMember nvs:DebtAndEquitySecuritiesMember ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:LongTermFinancialInvestmentsMember nvs:DebtAndEquitySecuritiesMember ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:LongTermFinancialInvestmentsMember nvs:DebtAndEquitySecuritiesMember ifrs-full:Level2OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:LongTermFinancialInvestmentsMember nvs:DebtAndEquitySecuritiesMember ifrs-full:Level2OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:LongTermFinancialInvestmentsMember nvs:DebtAndEquitySecuritiesMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:LongTermFinancialInvestmentsMember nvs:DebtAndEquitySecuritiesMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:LongTermFinancialInvestmentsMember nvs:DebtAndEquitySecuritiesMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:LongTermFinancialInvestmentsMember nvs:DebtAndEquitySecuritiesMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:LongTermFinancialInvestmentsMember nvs:FundInvestmentsMember ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:LongTermFinancialInvestmentsMember nvs:FundInvestmentsMember ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:LongTermFinancialInvestmentsMember nvs:FundInvestmentsMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:LongTermFinancialInvestmentsMember nvs:FundInvestmentsMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:LongTermFinancialInvestmentsMember nvs:FundInvestmentsMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:LongTermFinancialInvestmentsMember nvs:FundInvestmentsMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:LongTermFinancialInvestmentsMember nvs:NonCurrentContingentConsiderationReceivablesMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:LongTermFinancialInvestmentsMember nvs:NonCurrentContingentConsiderationReceivablesMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:LongTermFinancialInvestmentsMember nvs:NonCurrentContingentConsiderationReceivablesMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:LongTermFinancialInvestmentsMember nvs:NonCurrentContingentConsiderationReceivablesMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:LongTermFinancialInvestmentsMember ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:LongTermFinancialInvestmentsMember ifrs-full:Level1OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:LongTermFinancialInvestmentsMember ifrs-full:Level2OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:LongTermFinancialInvestmentsMember ifrs-full:Level2OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:LongTermFinancialInvestmentsMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:LongTermFinancialInvestmentsMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:LongTermFinancialInvestmentsMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:LongTermFinancialInvestmentsMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:CurrentFinancialLiabilitiesAtFairValueMember nvs:ContingentConsiderationPayablesMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:CurrentFinancialLiabilitiesAtFairValueMember nvs:ContingentConsiderationPayablesMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:CurrentFinancialLiabilitiesAtFairValueMember nvs:ContingentConsiderationPayablesMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:CurrentFinancialLiabilitiesAtFairValueMember nvs:ContingentConsiderationPayablesMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:CurrentFinancialLiabilitiesAtFairValueMember nvs:DerivativeFinancialInstrumentsMember ifrs-full:Level2OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:CurrentFinancialLiabilitiesAtFairValueMember nvs:DerivativeFinancialInstrumentsMember ifrs-full:Level2OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:CurrentFinancialLiabilitiesAtFairValueMember nvs:DerivativeFinancialInstrumentsMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:CurrentFinancialLiabilitiesAtFairValueMember nvs:DerivativeFinancialInstrumentsMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:CurrentFinancialLiabilitiesAtFairValueMember ifrs-full:Level2OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:CurrentFinancialLiabilitiesAtFairValueMember ifrs-full:Level2OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:CurrentFinancialLiabilitiesAtFairValueMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:CurrentFinancialLiabilitiesAtFairValueMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:CurrentFinancialLiabilitiesAtFairValueMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:CurrentFinancialLiabilitiesAtFairValueMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:NoncurrentFinancialLiabilitiesAtFairValueMember nvs:NoncurrentContingentConsiderationLiabilitiesMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:NoncurrentFinancialLiabilitiesAtFairValueMember nvs:NoncurrentContingentConsiderationLiabilitiesMember ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:NoncurrentFinancialLiabilitiesAtFairValueMember nvs:NoncurrentContingentConsiderationLiabilitiesMember ifrs-full:RecurringFairValueMeasurementMember 2026-06-30 0001114448 nvs:NoncurrentFinancialLiabilitiesAtFairValueMember nvs:NoncurrentContingentConsiderationLiabilitiesMember ifrs-full:RecurringFairValueMeasurementMember 2025-12-31 0001114448 nvs:FairValueDisclosureItemAmountsMember 2026-06-30 0001114448 nvs:FairValueDisclosureItemAmountsMember 2025-12-31 0001114448 nvs:CarryingReportedAmountFairValueDisclosure1Member 2026-06-30 0001114448 nvs:CarryingReportedAmountFairValueDisclosure1Member 2025-12-31 0001114448 ifrs-full:PropertyPlantAndEquipmentMember 2026-04-01 2026-06-30 0001114448 ifrs-full:PropertyPlantAndEquipmentMember 2025-04-01 2025-06-30 0001114448 ifrs-full:RightofuseAssetsMember 2026-04-01 2026-06-30 0001114448 ifrs-full:RightofuseAssetsMember 2025-04-01 2025-06-30 0001114448 nvs:IntangibleAssetsAndGoodwillMember 2026-04-01 2026-06-30 0001114448 nvs:IntangibleAssetsAndGoodwillMember 2025-04-01 2025-06-30 0001114448 ifrs-full:FinancialAssetsImpairedMember 2026-04-01 2026-06-30 0001114448 ifrs-full:FinancialAssetsImpairedMember 2025-04-01 2025-06-30 0001114448 ifrs-full:PropertyPlantAndEquipmentMember 2026-01-01 2026-06-30 0001114448 ifrs-full:PropertyPlantAndEquipmentMember 2025-01-01 2025-06-30 0001114448 ifrs-full:RightofuseAssetsMember 2026-01-01 2026-06-30 0001114448 ifrs-full:RightofuseAssetsMember 2025-01-01 2025-06-30 0001114448 nvs:IntangibleAssetsAndGoodwillMember 2026-01-01 2026-06-30 0001114448 nvs:IntangibleAssetsAndGoodwillMember 2025-01-01 2025-06-30 0001114448 ifrs-full:FinancialAssetsImpairedMember 2026-01-01 2026-06-30 0001114448 ifrs-full:FinancialAssetsImpairedMember 2025-01-01 2025-06-30 0001114448 nvs:CashAndCashEquivalentsRecognisedAsOfAcquisitionDateMember 2025-06-30 0001114448 country:GR nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember 2021-12-31 0001114448 country:GR nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember 2022-12-31 0001114448 country:GR nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember 2025-06-30 0001114448 country:US 2026-04-01 2026-06-30 0001114448 country:US 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember country:US 2026-04-01 2026-06-30 0001114448 srt:EuropeMember 2026-04-01 2026-06-30 0001114448 srt:EuropeMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember srt:EuropeMember 2026-04-01 2026-06-30 0001114448 nvs:AsiaAfricaAustralasiaMember 2026-04-01 2026-06-30 0001114448 nvs:AsiaAfricaAustralasiaMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:AsiaAfricaAustralasiaMember 2026-04-01 2026-06-30 0001114448 nvs:CanadaAndLatinAmericaMember 2026-04-01 2026-06-30 0001114448 nvs:CanadaAndLatinAmericaMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:CanadaAndLatinAmericaMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedMarketsMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedMarketsMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedMarketsMember 2026-04-01 2026-06-30 0001114448 nvs:EmergingGrowthMarketsMember 2026-04-01 2026-06-30 0001114448 nvs:EmergingGrowthMarketsMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EmergingGrowthMarketsMember 2026-04-01 2026-06-30 0001114448 country:US 2026-01-01 2026-06-30 0001114448 country:US 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember country:US 2026-01-01 2026-06-30 0001114448 srt:EuropeMember 2026-01-01 2026-06-30 0001114448 srt:EuropeMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember srt:EuropeMember 2026-01-01 2026-06-30 0001114448 nvs:AsiaAfricaAustralasiaMember 2026-01-01 2026-06-30 0001114448 nvs:AsiaAfricaAustralasiaMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:AsiaAfricaAustralasiaMember 2026-01-01 2026-06-30 0001114448 nvs:CanadaAndLatinAmericaMember 2026-01-01 2026-06-30 0001114448 nvs:CanadaAndLatinAmericaMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:CanadaAndLatinAmericaMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedMarketsMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedMarketsMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedMarketsMember 2026-01-01 2026-06-30 0001114448 nvs:EmergingGrowthMarketsMember 2026-01-01 2026-06-30 0001114448 nvs:EmergingGrowthMarketsMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EmergingGrowthMarketsMember 2026-01-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:EntrestoMember 2026-04-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:EntrestoMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:CardiovascularRenalAndMetabolicMember nvs:EntrestoMember 2026-04-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:LeqvioMember 2026-04-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:LeqvioMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:CardiovascularRenalAndMetabolicMember nvs:LeqvioMember 2026-04-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:VanrafiaMember 2026-04-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember 2026-04-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:CardiovascularRenalAndMetabolicMember 2026-04-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:CosentyxMember 2026-04-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:CosentyxMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:CosentyxMember 2026-04-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:IlarisMember 2026-04-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:IlarisMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:IlarisMember 2026-04-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:XolairMember 2026-04-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:XolairMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:XolairMember 2026-04-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:RhapsidoMember 2026-04-01 2026-06-30 0001114448 nvs:ImmunologyMember 2026-04-01 2026-06-30 0001114448 nvs:ImmunologyMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember 2026-04-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:KesimptaMember 2026-04-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:KesimptaMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember nvs:KesimptaMember 2026-04-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:ZolgensmaGroupMember 2026-04-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:ZolgensmaGroupMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember nvs:ZolgensmaGroupMember 2026-04-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:AimovigMember 2026-04-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:AimovigMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember nvs:AimovigMember 2026-04-01 2026-06-30 0001114448 nvs:NeuroscienceMember 2026-04-01 2026-06-30 0001114448 nvs:NeuroscienceMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:KisqaliMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:KisqaliMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:KisqaliMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:PluvictoMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:PluvictoMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:PluvictoMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:JakaviMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:JakaviMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:JakaviMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:TafinlarMekinistMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:TafinlarMekinistMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:TafinlarMekinistMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:ScemblixMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:ScemblixMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:ScemblixMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:LutatheraMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:LutatheraMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:LutatheraMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:FabhaltaMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:FabhaltaMember 2025-04-01 2025-06-30 0001114448 nvs:OncologyMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:SandostatinMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:SandostatinMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:SandostatinMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:ExforgeGroupMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:ExforgeGroupMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:ExforgeGroupMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:PromactaRevoladeMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:PromactaRevoladeMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:PromactaRevoladeMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:DiovanGroupMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:DiovanGroupMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:DiovanGroupMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:TasignaMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:TasignaMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:TasignaMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:LucentisMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:LucentisMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:LucentisMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:MyforticMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:MyforticMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:MyforticMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:PiqrayVijoiceMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:PiqrayVijoiceMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:PiqrayVijoiceMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:KymriahMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:KymriahMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:KymriahMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:ContractManufacturingMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:ContractManufacturingMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:ContractManufacturingMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:OtherProductsMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:OtherProductsMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:OtherProductsMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember 2025-04-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember 2026-04-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:EntrestoMember 2026-01-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:EntrestoMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:CardiovascularRenalAndMetabolicMember nvs:EntrestoMember 2026-01-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:LeqvioMember 2026-01-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:LeqvioMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:CardiovascularRenalAndMetabolicMember nvs:LeqvioMember 2026-01-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:VanrafiaMember 2026-01-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember 2026-01-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:CardiovascularRenalAndMetabolicMember 2026-01-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:CosentyxMember 2026-01-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:CosentyxMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:CosentyxMember 2026-01-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:IlarisMember 2026-01-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:IlarisMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:IlarisMember 2026-01-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:XolairMember 2026-01-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:XolairMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:XolairMember 2026-01-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:RhapsidoMember 2026-01-01 2026-06-30 0001114448 nvs:ImmunologyMember 2026-01-01 2026-06-30 0001114448 nvs:ImmunologyMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember 2026-01-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:KesimptaMember 2026-01-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:KesimptaMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember nvs:KesimptaMember 2026-01-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:ZolgensmaGroupMember 2026-01-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:ZolgensmaGroupMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember nvs:ZolgensmaGroupMember 2026-01-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:AimovigMember 2026-01-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:AimovigMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember nvs:AimovigMember 2026-01-01 2026-06-30 0001114448 nvs:NeuroscienceMember 2026-01-01 2026-06-30 0001114448 nvs:NeuroscienceMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:KisqaliMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:KisqaliMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:KisqaliMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:PluvictoMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:PluvictoMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:PluvictoMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:JakaviMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:JakaviMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:JakaviMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:TafinlarMekinistMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:TafinlarMekinistMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:TafinlarMekinistMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:ScemblixMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:ScemblixMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:ScemblixMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:LutatheraMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:LutatheraMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:LutatheraMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:FabhaltaMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:FabhaltaMember 2025-01-01 2025-06-30 0001114448 nvs:OncologyMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:SandostatinMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:SandostatinMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:SandostatinMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:ExforgeGroupMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:ExforgeGroupMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:ExforgeGroupMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:PromactaRevoladeMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:PromactaRevoladeMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:PromactaRevoladeMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:DiovanGroupMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:DiovanGroupMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:DiovanGroupMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:TasignaMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:TasignaMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:TasignaMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:LucentisMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:LucentisMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:LucentisMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:MyforticMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:MyforticMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:MyforticMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:PiqrayVijoiceMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:PiqrayVijoiceMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:PiqrayVijoiceMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:KymriahMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:KymriahMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:KymriahMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:ContractManufacturingMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:ContractManufacturingMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:ContractManufacturingMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:OtherProductsMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:OtherProductsMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:OtherProductsMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember 2025-01-01 2025-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember 2026-01-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:Top20ProductsMember country:US nvs:CosentyxMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:Top20ProductsMember country:US nvs:CosentyxMember 2026-04-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:CosentyxMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:CosentyxMember 2026-04-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:Top20ProductsMember nvs:CosentyxMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:Top20ProductsMember nvs:CosentyxMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:KisqaliMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:KisqaliMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:KisqaliMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:KisqaliMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:KisqaliMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:KisqaliMember 2026-04-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:Top20ProductsMember country:US nvs:KesimptaMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember nvs:Top20ProductsMember country:US nvs:KesimptaMember 2026-04-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:KesimptaMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:KesimptaMember 2026-04-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:Top20ProductsMember nvs:KesimptaMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember nvs:Top20ProductsMember nvs:KesimptaMember 2026-04-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember country:US nvs:EntrestoMember 2026-04-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:EntrestoMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:EntrestoMember 2026-04-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember nvs:EntrestoMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember nvs:EntrestoMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:PluvictoMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:PluvictoMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:PluvictoMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:PluvictoMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:PluvictoMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:PluvictoMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:JakaviMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:JakaviMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:JakaviMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:JakaviMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:TafinlarMekinistMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:TafinlarMekinistMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:TafinlarMekinistMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:TafinlarMekinistMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:TafinlarMekinistMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:TafinlarMekinistMember 2026-04-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:Top20ProductsMember country:US nvs:IlarisMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:Top20ProductsMember country:US nvs:IlarisMember 2026-04-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:IlarisMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:IlarisMember 2026-04-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:Top20ProductsMember nvs:IlarisMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:Top20ProductsMember nvs:IlarisMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:ScemblixMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:ScemblixMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:ScemblixMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:ScemblixMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:ScemblixMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:ScemblixMember 2026-04-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember country:US nvs:LeqvioMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember country:US nvs:LeqvioMember 2026-04-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:LeqvioMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:LeqvioMember 2026-04-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember nvs:LeqvioMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember nvs:LeqvioMember 2026-04-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:XolairMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:XolairMember 2026-04-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:Top20ProductsMember nvs:XolairMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:Top20ProductsMember nvs:XolairMember 2026-04-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:Top20ProductsMember country:US nvs:ZolgensmaGroupMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember nvs:Top20ProductsMember country:US nvs:ZolgensmaGroupMember 2026-04-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:ZolgensmaGroupMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:ZolgensmaGroupMember 2026-04-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:Top20ProductsMember nvs:ZolgensmaGroupMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember nvs:Top20ProductsMember nvs:ZolgensmaGroupMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember country:US nvs:SandostatinMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember country:US nvs:SandostatinMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:SandostatinMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:SandostatinMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:SandostatinMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:SandostatinMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:LutatheraMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:LutatheraMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:LutatheraMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:LutatheraMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:LutatheraMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:LutatheraMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:ExforgeGroupMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:ExforgeGroupMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:ExforgeGroupMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:ExforgeGroupMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:FabhaltaMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:FabhaltaMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:FabhaltaMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:FabhaltaMember 2026-04-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:FabhaltaMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:FabhaltaMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember country:US nvs:PromactaRevoladeMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember country:US nvs:PromactaRevoladeMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:PromactaRevoladeMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:PromactaRevoladeMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:PromactaRevoladeMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:PromactaRevoladeMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember country:US nvs:DiovanGroupMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember country:US nvs:DiovanGroupMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:DiovanGroupMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:DiovanGroupMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:DiovanGroupMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:DiovanGroupMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember country:US nvs:TasignaMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember country:US nvs:TasignaMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:TasignaMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:TasignaMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:TasignaMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:TasignaMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:LucentisMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:LucentisMember 2026-04-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:LucentisMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:LucentisMember 2026-04-01 2026-06-30 0001114448 nvs:Top20ProductsMember country:US 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:Top20ProductsMember country:US 2026-04-01 2026-06-30 0001114448 nvs:Top20ProductsMember nvs:RestOfTheWorldMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember 2026-04-01 2026-06-30 0001114448 nvs:Top20ProductsMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:Top20ProductsMember 2026-04-01 2026-06-30 0001114448 nvs:RestOfPortfolioMember country:US 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:RestOfPortfolioMember country:US 2026-04-01 2026-06-30 0001114448 nvs:RestOfPortfolioMember nvs:RestOfTheWorldMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:RestOfPortfolioMember nvs:RestOfTheWorldMember 2026-04-01 2026-06-30 0001114448 nvs:RestOfPortfolioMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:RestOfPortfolioMember 2026-04-01 2026-06-30 0001114448 nvs:RestOfTheWorldMember 2026-04-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:RestOfTheWorldMember 2026-04-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:Top20ProductsMember country:US nvs:CosentyxMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:Top20ProductsMember country:US nvs:CosentyxMember 2026-01-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:CosentyxMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:CosentyxMember 2026-01-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:Top20ProductsMember nvs:CosentyxMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:Top20ProductsMember nvs:CosentyxMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:KisqaliMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:KisqaliMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:KisqaliMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:KisqaliMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:KisqaliMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:KisqaliMember 2026-01-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:Top20ProductsMember country:US nvs:KesimptaMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember nvs:Top20ProductsMember country:US nvs:KesimptaMember 2026-01-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:KesimptaMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:KesimptaMember 2026-01-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:Top20ProductsMember nvs:KesimptaMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember nvs:Top20ProductsMember nvs:KesimptaMember 2026-01-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember country:US nvs:EntrestoMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember country:US nvs:EntrestoMember 2026-01-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:EntrestoMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:EntrestoMember 2026-01-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember nvs:EntrestoMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember nvs:EntrestoMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:PluvictoMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:PluvictoMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:PluvictoMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:PluvictoMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:PluvictoMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:PluvictoMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:JakaviMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:JakaviMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:JakaviMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:JakaviMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:TafinlarMekinistMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:TafinlarMekinistMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:TafinlarMekinistMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:TafinlarMekinistMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:TafinlarMekinistMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:TafinlarMekinistMember 2026-01-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:Top20ProductsMember country:US nvs:IlarisMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:Top20ProductsMember country:US nvs:IlarisMember 2026-01-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:IlarisMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:IlarisMember 2026-01-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:Top20ProductsMember nvs:IlarisMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:Top20ProductsMember nvs:IlarisMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:ScemblixMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:ScemblixMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:ScemblixMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:ScemblixMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:ScemblixMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:ScemblixMember 2026-01-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember country:US nvs:LeqvioMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember country:US nvs:LeqvioMember 2026-01-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:LeqvioMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:LeqvioMember 2026-01-01 2026-06-30 0001114448 nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember nvs:LeqvioMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:CardiovascularRenalAndMetabolicMember nvs:Top20ProductsMember nvs:LeqvioMember 2026-01-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:XolairMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:XolairMember 2026-01-01 2026-06-30 0001114448 nvs:ImmunologyMember nvs:Top20ProductsMember nvs:XolairMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:ImmunologyMember nvs:Top20ProductsMember nvs:XolairMember 2026-01-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:Top20ProductsMember country:US nvs:ZolgensmaGroupMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember nvs:Top20ProductsMember country:US nvs:ZolgensmaGroupMember 2026-01-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:ZolgensmaGroupMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:ZolgensmaGroupMember 2026-01-01 2026-06-30 0001114448 nvs:NeuroscienceMember nvs:Top20ProductsMember nvs:ZolgensmaGroupMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:NeuroscienceMember nvs:Top20ProductsMember nvs:ZolgensmaGroupMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember country:US nvs:SandostatinMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember country:US nvs:SandostatinMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:SandostatinMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:SandostatinMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:SandostatinMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:SandostatinMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:LutatheraMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:LutatheraMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:LutatheraMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:LutatheraMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:LutatheraMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:LutatheraMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember country:US nvs:ExforgeGroupMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember country:US nvs:ExforgeGroupMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:ExforgeGroupMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:ExforgeGroupMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:ExforgeGroupMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:ExforgeGroupMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:FabhaltaMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember country:US nvs:FabhaltaMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:FabhaltaMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:FabhaltaMember 2026-01-01 2026-06-30 0001114448 nvs:OncologyMember nvs:Top20ProductsMember nvs:FabhaltaMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:OncologyMember nvs:Top20ProductsMember nvs:FabhaltaMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember country:US nvs:PromactaRevoladeMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember country:US nvs:PromactaRevoladeMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:PromactaRevoladeMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:PromactaRevoladeMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:PromactaRevoladeMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:PromactaRevoladeMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember country:US nvs:DiovanGroupMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember country:US nvs:DiovanGroupMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:DiovanGroupMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:DiovanGroupMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:DiovanGroupMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:DiovanGroupMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember country:US nvs:TasignaMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember country:US nvs:TasignaMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:TasignaMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:TasignaMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:TasignaMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:TasignaMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:LucentisMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember nvs:LucentisMember 2026-01-01 2026-06-30 0001114448 nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:LucentisMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:EstablishedBrandsMember nvs:Top20ProductsMember nvs:LucentisMember 2026-01-01 2026-06-30 0001114448 nvs:Top20ProductsMember country:US 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:Top20ProductsMember country:US 2026-01-01 2026-06-30 0001114448 nvs:Top20ProductsMember nvs:RestOfTheWorldMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:Top20ProductsMember nvs:RestOfTheWorldMember 2026-01-01 2026-06-30 0001114448 nvs:Top20ProductsMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:Top20ProductsMember 2026-01-01 2026-06-30 0001114448 nvs:RestOfPortfolioMember country:US 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:RestOfPortfolioMember country:US 2026-01-01 2026-06-30 0001114448 nvs:RestOfPortfolioMember nvs:RestOfTheWorldMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:RestOfPortfolioMember nvs:RestOfTheWorldMember 2026-01-01 2026-06-30 0001114448 nvs:RestOfPortfolioMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:RestOfPortfolioMember 2026-01-01 2026-06-30 0001114448 nvs:RestOfTheWorldMember 2026-01-01 2026-06-30 0001114448 nvs:PoPChangeMember nvs:RestOfTheWorldMember 2026-01-01 2026-06-30 0001114448 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2025-04-01 2025-06-30 0001114448 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2026-01-01 2026-06-30 0001114448 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2025-01-01 2025-06-30 0001114448 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2026-04-01 2026-06-30 0001114448 nvs:BridgeLoan1Member nvs:AvidityBiosciencesIncMember ifrs-full:FloatingInterestRateMember 2026-06-30 0001114448 nvs:SOFR0.65USD500Million20262029NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt100.000Member 2026-06-30 0001114448 nvs:SOFR0.65USD500Million20262029NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt100.000Member 2026-01-01 2026-06-30 0001114448 nvs:A4.100USD1250Million20262029NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.883Member 2026-06-30 0001114448 nvs:A4.100USD1250Million20262029NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.883Member 2026-01-01 2026-06-30 0001114448 nvs:A4.400USD1750Million20262031NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.960Member 2026-06-30 0001114448 nvs:A4.400USD1750Million20262031NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.960Member 2026-01-01 2026-06-30 0001114448 nvs:A4.600USD2000Million20262033NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.574Member 2026-06-30 0001114448 nvs:A4.600USD2000Million20262033NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.574Member 2026-01-01 2026-06-30 0001114448 nvs:A4.900USD2250Million20262036NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.719Member 2026-06-30 0001114448 nvs:A4.900USD2250Million20262036NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.719Member 2026-01-01 2026-06-30 0001114448 nvs:A5.600USD1000Million20262046NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.536Member 2026-06-30 0001114448 nvs:A5.600USD1000Million20262046NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.536Member 2026-01-01 2026-06-30 0001114448 nvs:A5.700USD2250Million20262056NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.120Member 2026-06-30 0001114448 nvs:A5.700USD2250Million20262056NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.120Member 2026-01-01 2026-06-30 0001114448 nvs:A3.100EUR600Million20262032OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.525Member 2026-06-30 0001114448 nvs:A3.100EUR600Million20262032OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.525Member 2026-01-01 2026-06-30 0001114448 nvs:A3.500EUR600Million20262035OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member 2026-06-30 0001114448 nvs:A3.500EUR600Million20262035OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member 2026-01-01 2026-06-30 0001114448 nvs:A4.000EUR500Million20262041OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.833Member 2026-06-30 0001114448 nvs:A4.000EUR500Million20262041OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.833Member 2026-01-01 2026-06-30 0001114448 ifrs-full:NotLaterThanOneYearMember 2026-06-30 0001114448 ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2026-06-30 0001114448 ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2026-06-30 0001114448 ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2026-06-30 0001114448 ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2026-06-30 0001114448 nvs:LaterThanFiveYearsAndNotLaterThanSixYearsMember 2026-06-30 0001114448 nvs:LaterThanSixYearsMember 2026-06-30 0001114448 nvs:MyricxBioMember 2026-07-05 2026-07-05 iso4217:USD shares iso4217:USD shares pure iso4217:EUR 6-K Novartis AG 0001114448 2026-06-30 false --12-31 2026 Q2 14408000000 14054000000 543000000 782000000 3710000000 3322000000 11241000000 11514000000 3241000000 3442000000 2847000000 2727000000 410000000 548000000 813000000 1029000000 4750000000 4864000000 -2000000 -3000000 462000000 289000000 -17000000 -41000000 4269000000 4531000000 1012000000 507000000 3257000000 4024000000 3264000000 4041000000 -7000000 -17000000 1905000000 1948000000 1.71 2.07 1914000000 1960000000 1.71 2.06 27521000000 27287000000 954000000 1169000000 7169000000 6549000000 21306000000 21907000000 6381000000 6500000000 5587000000 5093000000 888000000 774000000 1241000000 1561000000 8985000000 9527000000 -5000000 -6000000 805000000 559000000 -67000000 -24000000 8108000000 8938000000 1695000000 1305000000 6413000000 7633000000 6420000000 7647000000 -7000000 -14000000 1906000000 1958000000 3.37 3.91 1915000000 1970000000 3.35 3.88 3257000000 4024000000 1000000 59000000 -173000000 -331000000 2114000000 -271000000 1941000000 819000000 44000000 38000000 3000000 857000000 47000000 586000000 1988000000 3843000000 6012000000 3854000000 6028000000 -11000000 -16000000 6413000000 7633000000 23000000 1000000 127000000 -233000000 -460000000 2834000000 -310000000 2602000000 567000000 480000000 167000000 -53000000 734000000 427000000 424000000 3029000000 6837000000 10662000000 6852000000 10674000000 -15000000 -12000000 10685000000 10782000000 1582000000 1570000000 26767000000 25567000000 42074000000 29411000000 69000000 98000000 5277000000 5438000000 2302000000 2348000000 5926000000 5275000000 94682000000 80489000000 6220000000 6269000000 9636000000 8937000000 218000000 205000000 74000000 155000000 7616000000 11435000000 3587000000 3459000000 27351000000 30460000000 122033000000 110949000000 736000000 766000000 49000000 50000000 40855000000 45414000000 41542000000 46130000000 404000000 419000000 41946000000 46549000000 37489000000 27935000000 1663000000 1657000000 5292000000 3397000000 3895000000 4133000000 48339000000 37122000000 4258000000 4456000000 9588000000 5602000000 274000000 263000000 2312000000 1969000000 15316000000 14988000000 31748000000 27278000000 80087000000 64400000000 122033000000 110949000000 736000000 -47000000 37252000000 571000000 38512000000 415000000 38927000000 3264000000 3264000000 -7000000 3257000000 590000000 590000000 -4000000 586000000 3264000000 590000000 3854000000 -11000000 3843000000 2000000 1172000000 1174000000 1174000000 0 319000000 319000000 319000000 2000000 2000000 2000000 -45000000 45000000 33000000 33000000 33000000 -2000000 -867000000 45000000 -824000000 -824000000 736000000 -49000000 39649000000 1206000000 41542000000 404000000 41946000000 766000000 -19000000 39839000000 -2217000000 38369000000 83000000 38452000000 4041000000 4041000000 -17000000 4024000000 1987000000 1987000000 1000000 1988000000 4041000000 1987000000 6028000000 -16000000 6012000000 15000000 2702000000 2717000000 2717000000 1000000 283000000 284000000 284000000 2000000 2000000 2000000 2000000 2000000 45000000 -45000000 23000000 23000000 23000000 -14000000 -2353000000 -45000000 -2412000000 2000000 -2410000000 766000000 -33000000 41527000000 -275000000 41985000000 69000000 42054000000 766000000 -50000000 44720000000 694000000 46130000000 419000000 46549000000 6420000000 6420000000 -7000000 6413000000 432000000 432000000 -8000000 424000000 6420000000 432000000 6852000000 -15000000 6837000000 9068000000 9068000000 9068000000 7000000 3056000000 3063000000 3063000000 30000000 -30000000 4000000 612000000 616000000 616000000 23000000 23000000 23000000 -80000000 80000000 -26000000 124000000 98000000 98000000 -30000000 1000000 -11491000000 80000000 -11440000000 -11440000000 736000000 -49000000 39649000000 1206000000 41542000000 404000000 41946000000 793000000 -53000000 46561000000 -3255000000 44046000000 80000000 44126000000 7647000000 7647000000 -14000000 7633000000 3027000000 3027000000 2000000 3029000000 7647000000 3027000000 10674000000 -12000000 10662000000 7818000000 7818000000 7818000000 29000000 5480000000 5509000000 5509000000 27000000 -42000000 15000000 7000000 550000000 557000000 557000000 33000000 33000000 33000000 1000000 1000000 1000000 2000000 47000000 -47000000 67000000 67000000 67000000 -27000000 20000000 -12681000000 -47000000 -12735000000 1000000 -12734000000 766000000 -33000000 41527000000 -275000000 41985000000 69000000 42054000000 3257000000 4024000000 3377000000 2954000000 1000000 1000000 44000000 39000000 339000000 248000000 398000000 41000000 -8000000 398000000 675000000 5901000000 6501000000 251000000 279000000 232000000 442000000 5882000000 6664000000 321000000 331000000 26000000 1000000 437000000 227000000 16000000 22000000 49000000 20000000 23000000 127000000 2720000000 1537000000 62000000 -11000000 30000000 36000000 87000000 30000000 218000000 -3000000 -3105000000 -2243000000 2871000000 2485000000 1199000000 2714000000 14000000 20000000 1982000000 20000000 603000000 208000000 850000000 67000000 66000000 -67000000 -215000000 -2020000000 -5213000000 757000000 -792000000 -18000000 382000000 739000000 -410000000 6877000000 7066000000 7616000000 6656000000 6413000000 7633000000 5868000000 5666000000 1000000 1000000 127000000 161000000 540000000 480000000 398000000 53000000 13000000 1185000000 1215000000 10631000000 12151000000 518000000 516000000 -555000000 -1326000000 9558000000 10309000000 667000000 585000000 31000000 11000000 898000000 1467000000 40000000 40000000 86000000 45000000 11704000000 127000000 2720000000 1537000000 60000000 -15000000 60000000 73000000 856000000 1881000000 215000000 -6000000 -14841000000 -1913000000 9068000000 7818000000 3074000000 5430000000 14000000 21000000 12900000000 39000000 1613000000 955000000 1406000000 140000000 135000000 11000000 -192000000 1559000000 -13761000000 -3724000000 -5365000000 -95000000 562000000 -3819000000 -4803000000 11435000000 11459000000 7616000000 6656000000 <div><div id="anchorId00221622"></div><div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">1. Basis of preparation</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">The consolidated financial statements of the Company are prepared in accordance with International Financial Reporting Standards (IFRS^®) Accounting Standards as issued by the International Accounting Standards Board. They are prepared in accordance with the historical cost convention, except for items that are required to be accounted for at fair value. </div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">These Condensed Interim Consolidated Financial Statements for the three month and six month period ended June 30, 2026, were prepared in accordance with International Accounting Standards (IAS®) Standards 34 Interim Financial Reporting and accounting policies set out in the 2025 Annual Report published on February 4, 2026.</div></div> <div><div id="anchorId00221632"></div><div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">2. Accounting policies</div><div><div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">The Company’s accounting policies are set out in Note 1 to the Consolidated Financial Statements in the 2025 Annual Report and conform with IFRS Accounting Standards as issued by the International Accounting Standards Board.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the period, which affect the reported amounts of revenues, expenses, assets, liabilities, and contingent amounts. </div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">Estimates are based on historical experience and other assumptions that are considered reasonable under the given circumstances and are regularly monitored. Actual outcomes and results could differ from those estimates and assumptions. Revisions to estimates are recognized in the period in which the estimate is revised.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">As disclosed in the 2025 Annual Report, goodwill, and the intangible assets not yet available for use (in-process research and development (IPR&amp;D)) are evaluated for impairment annually, or when facts and circumstances warrant. The intangible assets available for use (currently marketed products and other intangible assets) are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable. The amount of goodwill and intangible assets other than goodwill on the Company’s consolidated balance sheet has risen significantly in recent years, primarily from acquisitions. Impairment testing may lead to potentially significant impairment charges in the future that could have a materially adverse impact on the Company’s results of operations and financial condition.</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The Company’s activities are not subject to significant seasonal fluctuations.</div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Status of adoption of significant new or amended IFRS standards or interpretations</span></div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">No new IFRS Accounting Standards were adopted by the Company in 2026. There were no new IFRS Accounting Standards amendments or interpretations that became effective in 2026 and 2025, that had a material impact on the Company’s consolidated financial statements. </div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">In 2024, the International Accounting Standards Board issued the following new IFRS Accounting Standard, which is not yet effective:</div><div><span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">IFRS 18 Presentation and Disclosure in Financial Statements</span></div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">IFRS 18 Presentation and Disclosure in Financial Statements was issued by the International Accounting Standards Board in April 2024. IFRS 18 will become effective on January 1, 2027, and is required to be applied retrospectively to comparative periods presented, with early adoption permitted. Upon adoption, IFRS 18 replaces International Accounting Standards (IAS®) Standards 1 – Presentation of Financial Statements. </div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">IFRS 18 sets out new requirements focused on improving financial reporting by:</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">• requiring additional defined structure to the statement of profit or loss (i.e. consolidated statement of income), to reduce diversity in the reporting, by requiring five categories (operating, investing, financing, income taxes and discontinued operations) and defined subtotals and totals (operating income, income before financing, income taxes and net income),</div></div></div></div><div><div><div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">• requiring disclosures in the notes to the financial statements about management-defined performance measures (i.e. certain non-IFRS measures), and</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">• adding new principles for aggregation and disaggregation of information in the primary financial statements and notes.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">IFRS 18 will not affect the recognition or measurement of items in the financial statements, but it might change what an entity reports as its “operating profit or loss”, due to the classification of certain income and expense items between the five categories of the consolidated income statement. It might also change what an entity reports as operating activities, investing activities and financing activities within the statement of cash flows, due to the change in classification of certain cash flow items between these three categories of the cash flows statement.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The Company’s preliminary assessment of IFRS 18 impacts indicates that certain income and expense amounts are expected to be reclassified within the consolidated income statement. For example, portions of foreign currency results and monetary losses from hyperinflation accounting will move from non-operating to operating income and expense. These expected presentation changes will not affect reported net income. The consolidated statement of cash flows presentation will change. It will start with operating income instead of net income, and certain cash flows are expected to be reclassified among the operating, investing, and financing activities categories. For example, dividends received and interest received are expected to be reclassified from operating activities to investing activities, while interest paid is expected to be reclassified from operating activities to financing activities. These presentation changes will not affect the net change in cash and cash equivalents reported for the period.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">Novartis is currently finalizing its assessment of the impact of adopting IFRS 18, which will be effective January 1, 2027.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;margin-top:15px;">Based on the Company’s assessment, there were no other IFRS Accounting Standards, amendments or interpretations not yet effective in 2026 that would have been expected to have a material impact on the Company’s consolidated financial statements.</div></div></div></div> <div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">The Company’s accounting policies are set out in Note 1 to the Consolidated Financial Statements in the 2025 Annual Report and conform with IFRS Accounting Standards as issued by the International Accounting Standards Board.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the period, which affect the reported amounts of revenues, expenses, assets, liabilities, and contingent amounts. </div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">Estimates are based on historical experience and other assumptions that are considered reasonable under the given circumstances and are regularly monitored. Actual outcomes and results could differ from those estimates and assumptions. Revisions to estimates are recognized in the period in which the estimate is revised.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">As disclosed in the 2025 Annual Report, goodwill, and the intangible assets not yet available for use (in-process research and development (IPR&amp;D)) are evaluated for impairment annually, or when facts and circumstances warrant. The intangible assets available for use (currently marketed products and other intangible assets) are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable. The amount of goodwill and intangible assets other than goodwill on the Company’s consolidated balance sheet has risen significantly in recent years, primarily from acquisitions. Impairment testing may lead to potentially significant impairment charges in the future that could have a materially adverse impact on the Company’s results of operations and financial condition.</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The Company’s activities are not subject to significant seasonal fluctuations.</div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Status of adoption of significant new or amended IFRS standards or interpretations</span></div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">No new IFRS Accounting Standards were adopted by the Company in 2026. There were no new IFRS Accounting Standards amendments or interpretations that became effective in 2026 and 2025, that had a material impact on the Company’s consolidated financial statements. </div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">In 2024, the International Accounting Standards Board issued the following new IFRS Accounting Standard, which is not yet effective:</div><div><span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">IFRS 18 Presentation and Disclosure in Financial Statements</span></div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">IFRS 18 Presentation and Disclosure in Financial Statements was issued by the International Accounting Standards Board in April 2024. IFRS 18 will become effective on January 1, 2027, and is required to be applied retrospectively to comparative periods presented, with early adoption permitted. Upon adoption, IFRS 18 replaces International Accounting Standards (IAS®) Standards 1 – Presentation of Financial Statements. </div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">IFRS 18 sets out new requirements focused on improving financial reporting by:</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">• requiring additional defined structure to the statement of profit or loss (i.e. consolidated statement of income), to reduce diversity in the reporting, by requiring five categories (operating, investing, financing, income taxes and discontinued operations) and defined subtotals and totals (operating income, income before financing, income taxes and net income),</div></div><div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">• requiring disclosures in the notes to the financial statements about management-defined performance measures (i.e. certain non-IFRS measures), and</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">• adding new principles for aggregation and disaggregation of information in the primary financial statements and notes.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">IFRS 18 will not affect the recognition or measurement of items in the financial statements, but it might change what an entity reports as its “operating profit or loss”, due to the classification of certain income and expense items between the five categories of the consolidated income statement. It might also change what an entity reports as operating activities, investing activities and financing activities within the statement of cash flows, due to the change in classification of certain cash flow items between these three categories of the cash flows statement.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The Company’s preliminary assessment of IFRS 18 impacts indicates that certain income and expense amounts are expected to be reclassified within the consolidated income statement. For example, portions of foreign currency results and monetary losses from hyperinflation accounting will move from non-operating to operating income and expense. These expected presentation changes will not affect reported net income. The consolidated statement of cash flows presentation will change. It will start with operating income instead of net income, and certain cash flows are expected to be reclassified among the operating, investing, and financing activities categories. For example, dividends received and interest received are expected to be reclassified from operating activities to investing activities, while interest paid is expected to be reclassified from operating activities to financing activities. These presentation changes will not affect the net change in cash and cash equivalents reported for the period.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">Novartis is currently finalizing its assessment of the impact of adopting IFRS 18, which will be effective January 1, 2027.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;margin-top:15px;">Based on the Company’s assessment, there were no other IFRS Accounting Standards, amendments or interpretations not yet effective in 2026 that would have been expected to have a material impact on the Company’s consolidated financial statements.</div></div> <div><div id="anchorId00221686"></div><div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">3. Significant acquisitions of businesses</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">The following are the significant acquisitions of businesses where the Company applied the business combination acquisition method of accounting. </div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transaction in 2026</span></div><div><span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Acquisition of Avidity Biosciences, Inc.</span></div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">On October 25, 2025, Novartis entered into an agreement and plan of merger to acquire Avidity Biosciences, Inc. (“Avidity”), a US-based, publicly traded biotechnology company specializing in RNA therapeutics, with a focus on rare neuromuscular genetic disorders such as myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). </div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">Pursuant to the merger agreement, on February 27, 2026, following the satisfaction of the closing conditions, Novartis, through an indirect wholly owned subsidiary, acquired all outstanding shares of Avidity’s common stock for USD 72.00 per share in cash. The total consideration amounted to approximately USD 12.0 billion in cash on a fully diluted basis. The acquiring subsidiary merged with and into Avidity, resulting in Avidity becoming an indirect wholly owned subsidiary of Novartis. Avidity shares admitted to trading on NASDAQ were subsequently delisted. The acquisition was financed through a combination of available cash and third-party debt financing. </div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The fair value of the total purchase consideration was approximately USD 12.0 billion. The preliminary purchase price allocation resulted in net identifiable assets of approximately USD 10.6 billion. These comprised identifiable intangible assets, including IPR&amp;D, of USD 11.3 billion (of which approximately USD 7.5 billion is attributable to the DM1 IPR&amp;D intangible asset), marketable security funds of USD 0.7 billion (which were settled to cash on February 27, 2026 by Novartis), cash of USD 0.4 billion, other net assets of USD 0.1 billion, and net deferred tax liabilities of USD 1.9 billion. Goodwill arising from the acquisition amounted to approximately USD 1.4 billion. </div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The purchase price allocation is preliminary as the detailed valuation of certain acquired assets and liabilities, including identifiable intangible assets and deferred tax balances, has not yet been completed. The finalization of the purchase price allocation may result in changes to the amounts recognized for net identifiable assets and goodwill in subsequent reporting periods.</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The results of operations from the date of acquisition were not material.</div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transaction in 2025 </span></div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">In 2025, there were no acquisitions of businesses where the Company applied the business combination acquisition method of accounting.</div></div><div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Fair value of assets and liabilities acquired through business combinations</span></div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">The following table presents the fair value of the assets and liabilities acquired through business combinations and the total purchase consideration for the first half of 2026. In 2025, there were no business combinations. </div><div><div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/>(USD billions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br/> 2026</div></td><td></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">In-process research and development</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:20%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">11.3</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.6</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.2</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.7</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.4</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.1</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-2.5</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-0.1</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-0.1</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net identifiable assets acquired</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">10.6</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.4</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total purchase consideration for business combinations</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">12.0</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td colspan="4" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr></table></div></div></div><div><div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">The business combination in the first half of 2026 was Avidity. The goodwill arising out of the Avidity business combination is not tax deductible. It is primarily attributable to the deferred tax effects arising from the recognition of identifiable intangible assets for which no corresponding tax basis exists, expected synergies and the value of the acquired assembled workforce.</div><div style="padding-bottom:15px;padding-top:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">The following are the significant acquisitions where Novartis elected to apply the optional concentration test, resulting in the transaction being accounted for as assets separately acquired rather than as a business combination within the meaning of IFRS Accounting Standards. </div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transaction in 2026</span></div><div><span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Acquisition of Excellergy, Inc.</span></div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">On March 26, 2026, Novartis entered into an agreement and plan of merger to acquire all outstanding shares of Excellergy, Inc. (“Excellergy”), a US-based, private clinical-stage biotechnology company focused on the development of next-generation anti-IgE therapies for IgE-driven diseases. The transaction closed on June 24, 2026.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The purchase price consisted of cash consideration of USD 0.9 billion and potential additional milestones of up to USD 1.1 billion, which Excellergy shareholders are eligible to receive upon the achievement of specified milestones. The optional concentration test was applied as it indicated that substantially all of the fair value of the gross assets acquired was concentrated in an identifiable IPR&amp;D intangible asset.</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The cash purchase price was allocated to an IPR&amp;D intangible asset of USD 0.9 billion, and other net assets including cash of USD 5 million. Subsequent payments for the potential additional milestones will be recognized as additions to the intangible asset when the specified milestones have been achieved.</div><div><span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Acquisition of Pikavation Therapeutics, Inc.</span></div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">On March 18, 2026, Novartis entered into a stock purchase agreement to acquire Pikavation Therapeutics, Inc., (“Pikavation”), a wholly owned subsidiary of Synnovation Therapeutics, LLC (“Synnovation”), that holds a pan-mutant selective PI3Ka inhibitor IP, including SNV4818 phase 1 program. The transaction closed on May 28, 2026.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The purchase price consisted of cash consideration of USD 1.8 billion and potential additional milestones of up to USD 1.2 billion, which Synnovation is eligible to receive upon the achievement of specified milestones. The optional concentration test was applied as it indicated that substantially all of the fair value of the gross assets acquired was concentrated in an identifiable IPR&amp;D intangible asset.</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The cash purchase price was allocated to an IPR&amp;D intangible asset of USD 1.8 billion, and other net assets. Subsequent payments for the potential additional milestones will be recognized as additions to the intangible asset when the specified milestones have been achieved.</div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transaction in 2025</span></div><div><span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Acquisition of Tourmaline Bio, Inc.</span></div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">On September 8, 2025, Novartis entered into an agreement and plan of merger to acquire Tourmaline Bio, Inc. (“Tourmaline”), a US-based, publicly traded clinical-stage biopharmaceutical company focused on developing a treatment option for atherosclerotic cardiovascular disease.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">Pursuant to the merger agreement, on September 29, 2025, Novartis, through an indirect, wholly owned subsidiary, commenced a tender offer (the “Offer”) to acquire all of the outstanding shares of common stock of Tourmaline in exchange for USD 48.00 in cash per share. The tender offer expired at one minute past 11:59 p.m., New York City time on October 27, 2025 with a payment on October 28, 2025 in the amount of USD 1.4 billion for the tendered outstanding shares to the Tourmaline shareholders. On October 28, 2025, the acquiring subsidiary merged with and into Tourmaline, resulting in Tourmaline becoming an indirect wholly owned subsidiary of Novartis. Tourmaline shares admitted to trading on NASDAQ were subsequently delisted.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The cash purchase price consisted of cash consideration of USD 1.4 billion. The optional concentration test was applied as it indicated that substantially all of the fair value of the gross assets acquired was concentrated in an identifiable IPR&amp;D intangible asset.</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The cash purchase price was allocated to an IPR&amp;D intangible asset of USD 1.2 billion, and other net assets including cash and cash equivalents of USD 0.2 billion. </div></div></div></div><div><div><div><div><span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Option agreement to acquire a private clinical-stage biotech company</span></div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">On September 16, 2025, Novartis entered into an agreement granting it an option to acquire all outstanding shares of a private clinical-stage biotech company (the “Biotech company”). The option is subject to pre-defined terms and is exercisable at Novartis sole discretion. Management concluded that the terms of the option agreement conferred substantive control over the Biotech company, in accordance with the principles of IFRS Accounting Standards. Consequently, the Biotech company was consolidated into Novartis consolidated financial statements effective from September 2025. </div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">If Novartis decides to exercise the option to acquire, it would make a payment to the Biotech company’s shareholders, with potential additional payments, which they are eligible to receive upon achievement of specified milestones. The optional concentration test was applied as it indicated that substantially all of the fair value of the gross assets at the consolidation date was concentrated in an identifiable IPR&amp;D intangible asset.</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The purchase price as at the option agreement date was USD 0.4 billion. The amount was allocated to the net assets at the consolidation date, including USD 0.4 billion IPR&amp;D intangible assets and USD 18 million in cash and cash equivalents. A non-controlling interest of USD 0.4 billion was recognized in equity. Subsequent milestone-related payments will be recognized as additions to the intangible asset when the specified milestones are achieved.</div><div><span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Acquisition of Regulus Therapeutics Inc.</span></div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">On April 29, 2025, Novartis entered into an agreement and plan of merger to acquire Regulus Therapeutics Inc. (“Regulus”), a US-based, publicly traded clinical-stage biopharmaceutical company focused on developing microRNA therapeutics. Regulus lead development phase asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD). </div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">Pursuant to the merger agreement, on May 27, 2025, Novartis, through an indirect, wholly owned subsidiary, commenced a tender offer (the “Offer”) to acquire all of the outstanding shares of common stock of Regulus in exchange for (i) USD 7.00 in cash per Share, plus (ii) one contingent value right (each, a “CVR”) per Share, representing the right to receive one contingent payment of USD 7.00 in cash, upon the achievement of a specified regulatory milestone. The tender offer expired at one minute past 11:59 p.m., New York City time on June 24, 2025 with a payment of USD 0.7 billion for the outstanding shares to the Regulus shareholders for their tendered shares and the issuance of 1 CVR per share. Additionally, the liability related to the Regulus employee share plans amounted to USD 0.1 billion and was paid on July 11, 2025, with the issuance of 1 CVR per share. On June 25, 2025, the acquiring subsidiary merged with and into Regulus, resulting in Regulus becoming an indirect wholly owned subsidiary of Novartis. Regulus shares admitted to trading on NASDAQ were subsequently delisted.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The purchase price consisted of cash consideration of USD 0.8 billion and CVRs of up to USD 0.9 billion, which Regulus shareholders are eligible to receive upon the achievement of a specified regulatory milestone. The optional concentration test was applied as it indicated that substantially all of the fair value of the gross assets acquired was concentrated in an identifiable IPR&amp;D intangible asset.</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The cash purchase price was allocated to an IPR&amp;D intangible asset of USD 0.8 billion, and other net assets including cash and cash equivalents of USD 23 million. Subsequent payments for the potential CVRs upon achievement of the specified regulatory milestone will be recognized as additions to the intangible asset if the specified regulatory milestone is achieved. </div><div><span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Acquisition of Anthos Therapeutics, Inc.</span></div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">On February 10, 2025, Novartis entered into an agreement and plan of merger to acquire all of the outstanding shares of common stock of Anthos Therapeutics, Inc. (“Anthos”), a US-based, privately held clinical stage biopharmaceutical company with abelacimab, a late-stage medicine in development for the prevention of stroke and systematic embolism in patients with atrial fibrillation. The transaction closed on April 3, 2025.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The purchase price consisted of cash consideration of USD 0.9 billion and potential additional milestones of up to USD 2.1 billion, which Anthos shareholders are eligible to receive upon the achievement of specified milestones. The optional concentration test was applied as it indicated that substantially all of the fair value of the gross assets acquired was concentrated in an identifiable IPR&amp;D intangible asset.</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The cash purchase price was allocated to an IPR&amp;D intangible asset of USD 0.9 billion, and other net assets including cash and cash equivalents of USD 47 million. Subsequent payments for the potential additional milestones will be recognized as additions to the intangible asset when the specified milestones have been achieved. </div></div></div></div><div><div><div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Identifiable net assets acquired through acquisitions applying the optional concentration test</span></div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">The following table presents the identifiable net assets acquired through acquisitions applying the optional concentration test:</div></div></div><div><div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/>(USD billions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30,<br/> 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br/> 2025</div></td><td></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">In-process research and development</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.7</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">3.2</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets<sup style="white-space: nowrap"> 1</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">0.2</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents<sup style="white-space: nowrap"> 2</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">0.3</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current and non-current assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">0.1</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-0.2</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Identifiable net assets acquired through acquisitions applying the optional concentration test</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">2.7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">3.6</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td colspan="6" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="6"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹ Deferred tax assets are attributable to tax loss and tax credit carryforwards.</div></td></tr><tr style="vertical-align:bottom"><td colspan="6"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">²<span> H1 2026 includes cash of USD 5 million.</span></div></td></tr></table></div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">For significant pending transactions, see Note 10. Other interim disclosures — Commitments — Other commitments. </div></div></div></div> 72.00 12000000000.0 12000000000.0 10600000000 11300000000 7500000000 700000000 400000000 100000000 1900000000 1400000000 <div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/>(USD billions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br/> 2026</div></td><td></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">In-process research and development</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:20%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">11.3</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.6</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.2</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.7</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.4</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.1</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-2.5</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-0.1</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-0.1</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net identifiable assets acquired</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">10.6</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.4</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total purchase consideration for business combinations</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">12.0</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td colspan="4" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr></table></div></div> 11300000000 600000000 200000000 700000000 400000000 100000000 2500000000 100000000 100000000 10600000000 1400000000 12000000000.0 900000000 1100000000 900000000 5000000 1800000000 1200000000 1800000000 48.00 1400000000 1400000000 1200000000 200000000 400000000 400000000 18000000 400000000 7.00 7.00 700000000 1 100000000 1 800000000 900000000 800000000 23000000 900000000 2100000000 900000000 47000000 <div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/>(USD billions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30,<br/> 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br/> 2025</div></td><td></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">In-process research and development</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.7</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">3.2</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets<sup style="white-space: nowrap"> 1</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">0.2</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents<sup style="white-space: nowrap"> 2</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">0.3</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current and non-current assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">0.1</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-0.2</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Identifiable net assets acquired through acquisitions applying the optional concentration test</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">2.7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">3.6</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td colspan="6" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="6"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹ Deferred tax assets are attributable to tax loss and tax credit carryforwards.</div></td></tr><tr style="vertical-align:bottom"><td colspan="6"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">²<span> H1 2026 includes cash of USD 5 million.</span></div></td></tr></table></div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">For significant pending transactions, see Note 10. Other interim disclosures — Commitments — Other commitments. </div></div> 2700000000 3200000000 0.0 200000000 0.0 300000000 0.0 100000000 -0.0 200000000 2700000000 3600000000 5000000 <div><div id="anchorId00222192"></div><div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">4. Summary of equity attributable to Novartis AG shareholders </div><div><div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td align="center" colspan="3" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Number of outstanding shares (in millions)</div></td><td></td><td align="center" colspan="3" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Equity attributable to Novartis AG shareholders</div></td><td></td></tr><tr><td style=";height:3;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td></tr><tr><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td><td colspan="3" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td><td colspan="3" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td></tr><tr><td style=";height:3;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td></tr><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/> Note</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br/> 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"><br/> 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026<br/> USD millions</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025<br/> USD millions</div></td><td></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1 908.2</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">1 975.1</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">46 130</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">44 046</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be canceled</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-18.2</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-48.8</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-2 771</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-5 350</span></div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-2.0</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-1.6</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-292</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-159</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation plans</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">12.6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">11.1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">616</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">557</div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-23</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-33</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-9 068</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-7 818</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income of the period attributable to shareholders of Novartis AG</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6 420</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">7 647</div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income attributable to shareholders of Novartis AG</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">432</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">3 027</div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in non-controlling interests</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1</div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.3</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">0.1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">98</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">67</div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at June 30</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1 900.7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">1 935.9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">41 542</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">41 985</div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:bottom"><td colspan="12" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr></table></div></div></div><div><div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">4.1. The annual gross dividend to shareholders of Novartis AG amounted to USD 9.1 billion (2025: USD 7.8 billion). The net dividend payment to Novartis AG shareholders paid in March 2026 amounted to USD 6.2 billion (2025: USD 5.3 billion paid in March 2025). The USD 2.9 billion Swiss withholding tax on the gross dividend was paid at its due date in April 2026 (2025: USD 2.5 billion paid at its due date in April 2025).</div><div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">4.2. In July 2023, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD 15.0 billion share buyback. In June 2024, Novartis amended the arrangement to include the repurchase of an additional 8.7 million Novartis shares on the second trading line to mitigate the impact of share deliveries under the equity-based compensation plans for employees. These additional repurchases of 8.7 million shares concluded in October 2024. In June 2025, Novartis amended the arrangement to include the repurchase of an additional 10.7 million Novartis shares on the second trading line to mitigate the impact of share deliveries under the equity-based compensation plans for employees. These additional repurchases of 10.7 million shares concluded in August 2025. </div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The repurchases under the USD 15.0 billion share buyback that commenced in July 2023 concluded in July 2025.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">In July 2025, Novartis amended and restated its arrangement to repurchase Novartis shares on the second trading line under its new up-to USD 10.0 billion share buyback. </div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">In March 2026, Novartis replaced its July 2025 arrangement with a new irrevocable, non-discretionary arrangement with a bank to continue repurchasing Novartis shares on the second trading line under its up-to USD 10.0 billion share buyback. In May 2026, Novartis amended the arrangement to include the repurchase of an additional 12.1 million Novartis shares on the second trading line to mitigate the impact of share deliveries under the equity-based compensation plans for employees.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">Novartis is able to cancel this arrangement at any time but may be subject to a 90 day waiting period. As of June 30, 2026, and December 31, 2025, these waiting period conditions were not applicable and as a result, there was no requirement to record a liability under this arrangement as of June 30, 2026, and December 31, 2025.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;margin-top:15px;">4.3. Other movements include mainly the impact of the application of IAS Standards 29 “Financial Reporting in Hyperinflationary Economies,” for subsidiaries in hyperinflationary economies.</div></div></div></div> <div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td align="center" colspan="3" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Number of outstanding shares (in millions)</div></td><td></td><td align="center" colspan="3" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Equity attributable to Novartis AG shareholders</div></td><td></td></tr><tr><td style=";height:3;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td></tr><tr><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td><td colspan="3" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td><td colspan="3" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td></tr><tr><td style=";height:3;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td></tr><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/> Note</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br/> 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"><br/> 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026<br/> USD millions</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025<br/> USD millions</div></td><td></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1 908.2</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">1 975.1</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">46 130</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">44 046</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be canceled</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-18.2</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-48.8</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-2 771</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-5 350</span></div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-2.0</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-1.6</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-292</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-159</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation plans</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">12.6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">11.1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">616</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">557</div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-23</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-33</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-9 068</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-7 818</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income of the period attributable to shareholders of Novartis AG</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6 420</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">7 647</div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income attributable to shareholders of Novartis AG</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">432</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">3 027</div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in non-controlling interests</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1</div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.3</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">0.1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">98</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">67</div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at June 30</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1 900.7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">1 935.9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">41 542</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">41 985</div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:bottom"><td colspan="12" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr></table></div></div> 1908200000 1975100000 46130000000 44046000000 -18200000 -48800000 2771000000 5350000000 -2000000.0 -1600000 292000000 159000000 12600000 11100000 616000000 557000000 23000000 33000000 9068000000 7818000000 6420000000 7647000000 432000000 3027000000 1000000 100000 100000 98000000 67000000 1900700000 1935900000 41542000000 41985000000 9100000000 7800000000 6200000000 5300000000 2900000000 2500000000 15000000000.0 8700000 8700000 10700000 10700000 15000000000.0 10000000000.0 10000000000.0 12100000 <div><div id="anchorId00222644"></div><div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">5. Financial instruments</div><div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">The following table illustrates the three hierarchical levels for valuing financial instruments at fair value as of June 30, 2026, and December 31, 2025. For additional information on the hierarchies and other matters, please refer to the Consolidated Financial Statements in the 2025 Annual Report, published on February 4, 2026.</div><div><div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td></td><td align="center" colspan="3" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Level 1</div></td><td></td><td align="center" colspan="3" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Level 2</div></td><td></td><td align="center" colspan="3" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Level 3</div></td><td></td><td align="center" colspan="3" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total</div></td><td></td></tr><tr><td style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td></tr><tr><td style=";height:1;"></td><td style=";height:1;"></td><td colspan="3" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td><td colspan="3" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td><td colspan="3" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td><td colspan="3" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td></tr><tr><td style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td></tr><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/>(USD millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br/> 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br/> 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br/> 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br/> 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br/> 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br/> 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br/> 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br/> 2025</div></td><td></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents - debt securities</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:5%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:5%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:5%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:5%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:5%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:5%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:5%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:5%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">72</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">57</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">72</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">57</div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current contingent consideration receivables</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">111</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">101</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">111</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">101</div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current debt and equity securities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">15</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">12</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">12</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">18</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">27</div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets at fair value</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">15</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">15</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">73</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">57</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">123</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">113</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">211</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">185</div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current debt and equity securities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">448</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">255</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">498</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">529</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">952</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">791</div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">19</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">19</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">214</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">183</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">233</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">202</div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current contingent consideration receivables</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">742</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">758</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">742</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">758</div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit or loss</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">59</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">88</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">59</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">88</div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial assets at fair value</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">467</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">274</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1 513</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">1 558</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1 986</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">1 839</div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current contingent consideration liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-72</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-215</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-72</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-215</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-113</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-81</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-113</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-81</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial liabilities at fair value</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-113</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"><span>-81</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-72</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"><span>-215</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-185</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"><span>-296</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current contingent consideration liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-351</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"><span>-452</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-351</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"><span>-452</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:bottom"><td colspan="18" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr></table></div></div></div><div><div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">In the first half of 2026, there was one transfer of equity securities from Level 3 to Level 1 for USD 8 million due to Initial Public Offering of the invested company.</div></div></div><div><div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The carrying amount of non-current debt and equity securities, fund investments and non-current contingent consideration receivables totaling USD 2.0 billion at June 30, 2026 (USD 1.8 billion at December 31, 2025) is included in the line “Financial assets” of the consolidated balance sheets. The carrying amount of current contingent consideration liabilities of USD 0.1 billion at June 30, 2026 (USD 0.2 billion at December 31, 2025) is included in the line “Provisions and other current liabilities” of the consolidated balance sheets. The carrying amount of non-current contingent consideration liabilities of USD 0.4 billion at June 30, 2026 (USD 0.5 billion at December 31, 2025) is included in the line “Provisions and other non-current liabilities” of the consolidated balance sheets.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The fair value of straight bonds and floating rate bonds amounted to USD 39.2 billion at June 30, 2026 (USD 26.6 billion at December 31, 2025) compared with the carrying amount of USD 40.5 billion at June 30, 2026 (USD 27.9 billion at December 31, 2025). For all other financial assets and liabilities, the carrying amount is a reasonable approximation of the fair value. </div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;margin-top:15px;">The Company’s exposure to financial risks has not changed significantly during the period and there have been no major changes to the risk management department or in any risk management policies.</div></div></div></div> <div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td></td><td align="center" colspan="3" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Level 1</div></td><td></td><td align="center" colspan="3" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Level 2</div></td><td></td><td align="center" colspan="3" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Level 3</div></td><td></td><td align="center" colspan="3" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total</div></td><td></td></tr><tr><td style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td></tr><tr><td style=";height:1;"></td><td style=";height:1;"></td><td colspan="3" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td><td colspan="3" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td><td colspan="3" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td><td colspan="3" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td></tr><tr><td style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td></tr><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/>(USD millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br/> 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br/> 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br/> 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br/> 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br/> 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br/> 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br/> 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, <br/> 2025</div></td><td></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents - debt securities</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:5%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:5%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:5%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:5%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:5%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:5%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:5%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:5%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">72</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">57</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">72</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">57</div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current contingent consideration receivables</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">111</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">101</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">111</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">101</div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current debt and equity securities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">15</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">12</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">12</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">18</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">27</div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets at fair value</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">15</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">15</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">73</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">57</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">123</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">113</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">211</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">185</div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current debt and equity securities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">448</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">255</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">498</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">529</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">952</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">791</div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">19</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">19</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">214</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">183</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">233</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">202</div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current contingent consideration receivables</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">742</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">758</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">742</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">758</div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit or loss</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">59</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">88</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">59</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">88</div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial assets at fair value</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">467</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">274</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1 513</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">1 558</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1 986</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">1 839</div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current contingent consideration liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-72</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-215</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-72</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-215</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-113</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-81</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-113</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-81</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial liabilities at fair value</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-113</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"><span>-81</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-72</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"><span>-215</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-185</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"><span>-296</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current contingent consideration liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-351</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"><span>-452</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-351</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"><span>-452</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="18" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:bottom"><td colspan="18" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr></table></div></div> 10000000 10000000 72000000 57000000 72000000 57000000 111000000 101000000 111000000 101000000 5000000 15000000 1000000 12000000 12000000 18000000 27000000 15000000 15000000 73000000 57000000 123000000 113000000 211000000 185000000 448000000 255000000 6000000 7000000 498000000 529000000 952000000 791000000 19000000 19000000 214000000 183000000 233000000 202000000 742000000 758000000 742000000 758000000 59000000 88000000 59000000 88000000 467000000 274000000 6000000 7000000 1513000000 1558000000 1986000000 1839000000 72000000 215000000 72000000 215000000 113000000 81000000 113000000 81000000 113000000 81000000 72000000 215000000 185000000 296000000 351000000 452000000 351000000 452000000 In the first half of 2026, there was one transfer of equity securities from Level 3 to Level 1 for USD 8 million due to Initial Public Offering of the invested company. 8000000 2000000000.0 1800000000 100000000 200000000 400000000 500000000 39200000000 26600000000 40500000000 27900000000 <div><div id="anchorId00223451"></div><div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">6. Details to the consolidated statements of cash flows </div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">6.1. Non-cash items and other adjustments </span></div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">The following tables show the reversal of non-cash items and other adjustments in the consolidated statements of cash flows. </div><div><div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2025</div></td><td></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Property, plant and equipment</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">261</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">245</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Right-of-use assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">78</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">68</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Intangible assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 061</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">943</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Financial assets<sup style="white-space: nowrap"> 1</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-4</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">466</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">665</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gains on disposal on property, plant and equipment; intangible assets; other non-current assets; and other adjustments on financial assets and other non-current assets, net</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-247</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-67</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation plans</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">267</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">267</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Loss from associated companies</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">3</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 012</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">507</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">479</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">330</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-8</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-3</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">3 377</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">2 954</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:bottom"><td colspan="6" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="6"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹ Includes fair value changes</div></td></tr></table></div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025</div></td><td></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Property, plant and equipment</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">559</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">462</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Right-of-use assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">151</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">133</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Intangible assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 918</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 815</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Financial assets<sup style="white-space: nowrap"> 1</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-14</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">37</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">536</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">847</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gains on disposal on property, plant and equipment; intangible assets; other non-current assets; and other adjustments on financial assets and other non-current assets, net</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-406</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-45</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation plans</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">570</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">529</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Loss from associated companies</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">6</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 695</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 305</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">872</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">583</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-18</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-6</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">5 868</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">5 666</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:bottom"><td colspan="6" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="6"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹ Includes fair value changes</div></td></tr></table></div></div></div><div><div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">6.2. Cash flows from changes in working capital and other operating cash flow items included in the net cash flows from operating activities </span></div></div></div><div><div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025</div></td><td></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase)/decrease in inventories</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">30</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-44</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-65</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">11</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in trade receivables</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-256</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-167</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-760</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-1 210</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Decrease in trade payables</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-184</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-143</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-237</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-315</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current and non-current assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">22</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">172</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">368</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-252</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other current liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">620</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">624</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">139</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">440</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">232</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">442</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-555</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"><span>-1 326</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 3px;"></td></tr></table></div></div></div></div><div><div><div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">6.3. Cash flows related to acquisitions of businesses</span></div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">The following table is a summary of the cash flow impact of acquisitions of businesses:</div></div></div><div><div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025</div></td><td></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total purchase consideration for business combinations</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">0</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">0</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-12 031</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">0</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired cash</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">371</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables, net</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-23</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-127</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-44</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-127</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Acquisitions of businesses</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-23</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"><span>-127</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-11 704</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"><span>-127</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 2px;"></td></tr></table></div></div></div><div><div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Note 3 provides disclosure of the fair value of assets and liabilities acquired through business combinations. All considerations paid for acquisitions were in cash.</div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">6.4. Cash flows used for acquisitions by applying the optional concentration test</span></div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">In the current-year period, the total cash consideration paid for acquisitions where the Company elected to apply the optional concentration test to determine that the transaction is not a business combination within the meaning of IFRS Accounting Standards, and to account for the acquisition as assets separately acquired amounted to USD 2.7 billion, net of cash acquired of USD 5 million (Q2 2026: USD 2.7 billion, net of cash acquired of USD 5 million; Q2 2025 and H1 2025: USD 1.5 billion, net of cash and cash equivalents acquired of USD 70 million).</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">Note 3 provides disclosure of the identifiable net assets acquired through acquisitions where the Company elected to apply the optional concentration test. All consideration paid for acquisitions were in cash.</div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">6.5. Cash flows related to divestments of businesses </span></div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Cash flows related to divestments of businesses were not material. All considerations received or paid related to divestments were in cash.</div></div></div></div> <div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2025</div></td><td></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Property, plant and equipment</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">261</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">245</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Right-of-use assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">78</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">68</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Intangible assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 061</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">943</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Financial assets<sup style="white-space: nowrap"> 1</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-4</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">466</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">665</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gains on disposal on property, plant and equipment; intangible assets; other non-current assets; and other adjustments on financial assets and other non-current assets, net</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-247</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-67</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation plans</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">267</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">267</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Loss from associated companies</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">3</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 012</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">507</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">479</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">330</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-8</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-3</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">3 377</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">2 954</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:bottom"><td colspan="6" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="6"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹ Includes fair value changes</div></td></tr></table></div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025</div></td><td></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Property, plant and equipment</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">559</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:14%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">462</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Right-of-use assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">151</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">133</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Intangible assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 918</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 815</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Financial assets<sup style="white-space: nowrap"> 1</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-14</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">37</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">536</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">847</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gains on disposal on property, plant and equipment; intangible assets; other non-current assets; and other adjustments on financial assets and other non-current assets, net</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-406</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-45</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation plans</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">570</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">529</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Loss from associated companies</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">6</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 695</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 305</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">872</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">583</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-18</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-6</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">5 868</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">5 666</div></td><td style="text-align:right"></td></tr><tr><td colspan="6" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:bottom"><td colspan="6" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="6"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹ Includes fair value changes</div></td></tr></table></div></div> 261000000 245000000 78000000 68000000 1061000000 943000000 6000000 -4000000 466000000 665000000 -247000000 -67000000 267000000 267000000 -2000000 -3000000 1012000000 507000000 -479000000 -330000000 -8000000 -3000000 3377000000 2954000000 559000000 462000000 151000000 133000000 1918000000 1815000000 -14000000 37000000 536000000 847000000 -406000000 -45000000 570000000 529000000 -5000000 -6000000 1695000000 1305000000 -872000000 -583000000 -18000000 -6000000 5868000000 5666000000 <div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025</div></td><td></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase)/decrease in inventories</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">30</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-44</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-65</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">11</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in trade receivables</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-256</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-167</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-760</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-1 210</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Decrease in trade payables</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-184</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-143</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-237</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-315</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current and non-current assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">22</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">172</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">368</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-252</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other current liabilities</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">620</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">624</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">139</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">440</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">232</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">442</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-555</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"><span>-1 326</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 3px;"></td></tr></table></div></div> 30000000 -44000000 -65000000 11000000 -256000000 -167000000 -760000000 -1210000000 -184000000 -143000000 -237000000 -315000000 22000000 172000000 368000000 -252000000 620000000 624000000 139000000 440000000 232000000 442000000 -555000000 -1326000000 <div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025</div></td><td></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total purchase consideration for business combinations</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">0</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">0</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-12 031</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:8%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">0</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired cash</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">371</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables, net</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-23</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-127</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-44</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-127</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Acquisitions of businesses</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-23</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"><span>-127</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-11 704</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"><span>-127</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="12" style="border-bottom: solid #000000 2px;"></td></tr></table></div></div> -0 -0 12031000000 -0 371000000 -23000000 -127000000 -44000000 -127000000 23000000 127000000 11704000000 127000000 2700000000 5000000 2700000000 5000000 1500000000 70000000 <div><div id="anchorId00224227"></div><div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">7. Legal proceedings update</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings, including litigations, arbitrations and governmental investigations, that arise from time to time. Legal proceedings are inherently unpredictable. As a result, the Company may become subject to substantial liabilities that may not be covered by insurance and may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow. Note 20 to the Consolidated Financial Statements in our 2025 Annual Report and 2025 Form 20-F contains a summary as of the date of these reports of significant legal proceedings to which Novartis or its subsidiaries were a party. The following is a summary as of July 20, 2026, of significant developments in those proceedings, as well as any new significant proceedings commenced since the date of the 2025 Annual Report and 2025 Form 20-F.</div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Investigations and related litigations</span></div><div><span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Southern District of New York (S.D.N.Y.) <i>Gilenya</i> marketing practices investigation and litigation</span></div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">In 2013, Novartis Pharmaceuticals Corporation (NPC) received a civil investigative demand from the United States Attorney’s Office for the S.D.N.Y. requesting the production of documents and information relating to marketing practices for <i>Gilenya</i>, including the remuneration of healthcare providers in connection therewith. In 2017, the S.D.N.Y. and New York State declined to intervene in claims raised by an individual relator in a qui tam complaint. In 2022, NPC’s motion to dismiss this complaint was granted. In December 2024, the appeals court affirmed in part but remanded in part, sending the case back to the district court for further proceedings. In March 2026, the district court denied Novartis motion to dismiss and the case proceeded to discovery. The claims are being vigorously contested.</div><div><span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Inflation Reduction Act (IRA) litigation</span></div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">In 2023, following the U.S. government’s selection of Entresto for the first round of the IRA’s “Medicare Drug Price Negotiation Program,” NPC filed a complaint in the U.S. District Court (USDC) for the District of New Jersey on the grounds that those drug price-setting provisions are unconstitutional under the First, Fifth and Eighth Amendments to the U.S. Constitution. In October 2024, the court granted the government’s motion for summary judgment. NPC appealed to the Third Circuit and in September 2025, the Third Circuit affirmed. In May 2026, the U.S. Supreme Court declined to hear NPC’s petition, concluding this litigation.</div><div><span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Greece investigation</span></div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">The Greek authorities are investigating legacy allegations of potentially inappropriate economic benefits to healthcare providers (HCPs), government officials and others in Greece. These authorities include the Greek Coordinating Body for Inspection and Control, and the Greek Body of Prosecution of Financial Crime (SDOE), from which the Company received a summons in 2018 and 2020. Novartis has cooperated in these investigations. In 2021, SDOE imposed on Novartis Hellas a fine equivalent to approximately USD 1.2 million; Novartis Hellas appealed the fine and, in September 2023, the Court overturned the decision and fine. The Greek State appealed. In June 2026, the Court of Appeal upheld the decision annulling the fine. In 2022, the Greek State served a civil lawsuit on Novartis Hellas, seeking approximately USD 225 million for moral damages allegedly arising from the conduct that was the subject of the Company’s 2020 settlement with the US Department of Justice regarding allegations of inappropriate economic benefits in Greece that was disclosed in the 2020 Annual Report and the 2020 Form 20-F. In May 2025, the court issued its decision rejecting the claims of the Greek State, which the Greek State appealed in October 2025. In June 2025, the National Social Security Fund of Greece filed a civil lawsuit against Novartis seeking approximately EUR 229 million for moral damages arising from the same facts. The claims will be vigorously contested.</div><div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">In addition to the matters described above, there have been other non-material developments in the other legal matters described in Note 20 to the Consolidated Financial Statements contained in our 2025 Annual Report and 2025 Form 20-F.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;margin-top:15px;">Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided.</div></div> 1200000 225000000 229000000 <div><div id="anchorId00224266"></div><div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">8. Operating segment </div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Novartis operates as a single global operating segment innovative medicines company that is engaged in the research, development, manufacturing, distribution, marketing and sale of a broad range of innovative pharmaceuticals medicines, with a focus on the core therapeutic areas: cardiovascular, renal and metabolic; immunology; neuroscience; oncology; and established brands. The Company’s research, development, manufacturing and supply of products and functional activities are managed globally on a vertically integrated basis. Commercial efforts that coordinate marketing, sales and distribution of these products are organized by geographic region, therapeutic area and established brands.</div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The Executive Committee of Novartis (ECN), chaired by the CEO, is the governance body responsible for allocating resources and assessing the business performance of the operating segment of the Company on a global basis and is the chief operating decision-maker (CODM) for the Company. </div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The determination of a single operating segment is consistent with the financial information regularly reviewed by the CODM for purposes of assessing performance and allocating resources. </div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">See Note 9 for revenues and geographic information disclosures.</div></div> <div><div id="anchorId00224278"></div><div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">9. Revenues and geographic information</div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net sales to third parties</span></div><div><div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net sales to third parties by region¹</span></div><div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000; "><b>Second quarter</b></div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2026<br/> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2025<br/> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change<br/> USD</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change<br/> cc<sup style="white-space: nowrap">2</sup></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2026<br/> % of total</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2025<br/> % of total</div></td><td></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   US</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5 954</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">6 249</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-5</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-5</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">41</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">44</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Europe</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4 441</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">4 170</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">31</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">30</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Asia/Africa/Australasia</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3 018</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">2 713</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">11</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">11</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">21</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">19</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Canada and Latin America</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">995</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">922</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">7</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">14 408</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">14 054</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">3</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">100</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">100</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">   Of which in established markets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10 536</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">10 537</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">73</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">75</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">   Of which in emerging growth markets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3 872</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">3 517</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">27</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">25</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td colspan="14"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹ Net sales to third parties by location of customer. Emerging growth markets comprise all markets other than the established markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. Novartis definition of Western Europe includes Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Luxembourg, Malta, The Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.</div></td></tr><tr style="vertical-align:bottom"><td colspan="14"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">² Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 43.</div></td></tr></table></div><div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000; "><b>First half</b></div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026<br/> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025<br/> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change<br/> USD</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change<br/> cc<sup style="white-space: nowrap">2</sup></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026<br/> % of total</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025<br/> % of total</div></td><td></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   US</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10 913</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">11 961</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-9</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-9</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">40</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">44</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Europe</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8 627</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">8 075</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">31</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">30</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Asia/Africa/Australasia</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6 038</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">5 485</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">22</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">20</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Canada and Latin America</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 943</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 766</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">6</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">27 521</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">27 287</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-2</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">100</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">100</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">   Of which in established markets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">19 798</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">20 206</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-2</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-4</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">72</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">74</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">   Of which in emerging growth markets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7 723</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">7 081</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">28</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">26</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td colspan="14" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="14"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹ Net sales to third parties by location of customer. Emerging growth markets comprise all markets other than the established markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. Novartis definition of Western Europe includes Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Luxembourg, Malta, The Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.</div></td></tr><tr style="vertical-align:bottom"><td colspan="14"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">² Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 43.</div></td></tr></table></div></div></div></div><div><div><div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net sales to third parties by core therapeutic area and established brands </span></div><div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000; "><b>Second quarter</b></div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change</div></td><td></td></tr><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> cc<sup style="white-space: nowrap">1</sup></div></td><td></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular, renal and metabolic</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 181</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">2 357</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-50</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-51</span></div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Leqvio</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">480</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">298</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">61</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">59</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Vanrafia</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">27</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cardiovascular, renal and metabolic</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1 688</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">2 655</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-36</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-37</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 824</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 629</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">12</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">550</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">477</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap"> 2</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">342</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">443</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-23</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-25</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Rhapsido</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">64</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total immunology</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">2 780</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">2 549</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">8</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 424</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 077</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">32</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">32</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Zolgensma</i> Group</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">365</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">297</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">23</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">20</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">88</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">83</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total neuroscience</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1 877</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">1 457</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">29</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">28</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Oncology</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 695</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 177</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">44</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">43</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Pluvicto</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">651</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">454</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">43</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">43</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">576</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">524</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Tafinlar</i> + <i>Mekinist</i></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">581</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">573</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Scemblix</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">562</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">298</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">89</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">89</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">225</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">207</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Fabhalta<sup style="white-space: nowrap"> 3</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">225</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">120</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">88</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">88</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total oncology<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">4 515</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">3 353</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">35</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">34</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established brands</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Sandostatin</i> Group</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">302</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">303</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-1</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">191</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">191</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-3</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">179</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">502</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-64</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-65</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">160</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">154</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">142</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">327</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-57</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-58</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">126</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">173</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-27</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-30</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Myfortic<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">105</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">102</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray/Vijoice<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">123</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">111</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">11</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">88</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">99</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-11</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-10</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contract manufacturing</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">472</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">276</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">71</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">68</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 660</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 802</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-8</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-9</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total established brands<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">3 548</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">4 040</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-12</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-14</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total net sales to third parties</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">14 408</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">14 054</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">3</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td colspan="10" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹ Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 43.</div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">² Net sales to third parties reflect <i>Xolair</i> sales for all indications.<b></b><b></b><b></b><b></b><b></b><b></b><b></b></div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">³ Net sales to third parties reflect <i>Fabhalta</i> sales for all indications.<b></b><b></b><b></b><b></b><b></b><b></b><b></b></div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">⁴ Reclassified to conform with 2026 presentation of brands by therapeutic area and established brands.</div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="10" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div></td></tr></table></div></div></div></div><div><div><div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net sales to third parties by core therapeutic area and established brands </span></div><div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000; "><b>First half</b></div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change</div></td><td></td></tr><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> cc<sup style="white-space: nowrap">1</sup></div></td><td></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular, renal and metabolic</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 486</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">4 618</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-46</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-48</span></div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Leqvio</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">932</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">555</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">68</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">64</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Vanrafia</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">43</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cardiovascular, renal and metabolic</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">3 461</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">5 173</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-33</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-35</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3 390</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">3 163</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 025</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">896</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">14</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">13</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap"> 2</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">730</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">899</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-19</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-22</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Rhapsido</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">101</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total immunology</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">5 246</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">4 958</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">3</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 588</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 976</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">31</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">29</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Zolgensma</i> Group</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">667</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">624</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">183</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">159</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total neuroscience</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">3 438</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">2 759</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">25</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">22</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Oncology</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3 211</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">2 133</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">51</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">48</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Pluvicto</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 293</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">825</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">57</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">55</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 133</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 016</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">12</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Tafinlar</i> + <i>Mekinist</i></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 074</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 125</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-5</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-7</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Scemblix</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">995</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">536</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">86</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">85</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">436</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">400</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Fabhalta<sup style="white-space: nowrap"> 3</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">394</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">201</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">96</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">94</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total oncology<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">8 536</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">6 236</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">37</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">34</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established brands</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Sandostatin</i> Group</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">589</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">620</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-5</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-7</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">394</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">370</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">363</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 048</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-65</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-66</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">310</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">304</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-2</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">297</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">704</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-58</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-59</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">230</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">362</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-36</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-40</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Myfortic<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">216</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">201</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray/Vijoice<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">204</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">211</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-3</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-4</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">169</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">199</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-15</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-16</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contract manufacturing</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">824</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">619</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">33</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">27</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3 244</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">3 523</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-8</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-11</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total established brands<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">6 840</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">8 161</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-16</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-19</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total net sales to third parties</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">27 521</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">27 287</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-2</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td colspan="10" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹ Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 43.</div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">² Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">³ Net sales to third parties reflect <i>Fabhalta</i> sales for all indications.</div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">⁴ Reclassified to conform with 2026 presentation of brands by therapeutic area and established brands.</div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="10" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div></td></tr></table></div></div></div></div><div><div><div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net sales to third parties¹ of the top 20 brands in 2026</span></div><div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000; "><b>Second quarter</b></div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td align="center" colspan="3" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> US</div></td><td></td><td align="center" colspan="5" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of world</div></td><td></td><td align="center" colspan="5" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total</div></td><td></td></tr><tr><td style=";height:3;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="5" style=";height:3;"></td><td style=";height:1;"></td><td colspan="5" style=";height:3;"></td><td style=";height:1;"></td></tr><tr><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td colspan="3" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td><td colspan="5" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td><td colspan="5" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td></tr><tr><td style=";height:3;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="5" style=";height:3;"></td><td style=";height:1;"></td><td colspan="5" style=";height:3;"></td><td style=";height:1;"></td></tr><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brands</div></td><td></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by therapeutic area or established brands</div></td><td></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Key indications</div></td><td></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change USD/cc<sup style="white-space: nowrap">2</sup></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change USD</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change cc<sup style="white-space: nowrap">2</sup></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change USD</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change cc<sup style="white-space: nowrap">2</sup></div></td><td></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;width:12%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div></td><td style="text-align:right;width:1%;"></td><td style=";width:12%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology </div></td><td style="text-align:right;width:1%;"></td><td style=";width:12%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA), hidradenitis suppurativa (HS)</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 069</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">16</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">755</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 824</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">12</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2- metastatic breast cancer and early breast cancer</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 045</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">39</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">650</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">52</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">49</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 695</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">44</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">43</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing forms of multiple sclerosis (MS)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">942</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">32</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">482</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">32</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">30</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 424</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">32</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">32</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, renal and metabolic</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure, hypertension</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-2</span><sup style="white-space: nowrap"> 5 </sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm </div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 183</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 181</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-50</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-51</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Pluvicto</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PSMA-positive mCRPC patients post-ARPI, pre- and post-Taxane</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">493</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">38</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">158</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">65</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">62</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">651</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">43</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">43</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF), polycythemia vera (PV), graft-versus-host disease (GvHD)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">576</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">576</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Tafinlar</i> + <i>Mekinist</i></div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic and adjuvant melanoma, advanced non-small cell lung cancer (NSCLC), tumor agnostic with BRAF mutation indication, pediatric low grade glioma (pLGG)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">197</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-20</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">384</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">17</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">581</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">315</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">21</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">235</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">550</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Scemblix</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP); Ph+ CML in CP with the T315I mutation</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">369</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">93</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">193</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">80</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">82</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">562</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">89</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">89</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Leqvio</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, renal and metabolic </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Atherosclerotic cardiovascular disease (ASCVD)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">214</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">55</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">266</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">66</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">63</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">480</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">61</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">59</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap"> 3</sup></div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps, food allergy (FA)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">342</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-23</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-25</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">342</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-23</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-25</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Zolgensma</i> Group</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy (SMA)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">152</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">58</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">213</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">365</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">23</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">20</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Sandostatin</i> Group</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors, acromegaly</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">177</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-5</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">125</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">302</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-1</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GEP-NETs gastroenteropancreatic neuroendocrine tumors</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">163</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">62</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">225</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">191</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-3</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">191</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-3</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Fabhalta<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Paroxysmal Nocturnal Hemoglobinuria (PNH), IgA Nephropathy (IgAN), Adult C3 Glomerulopathy (C3G)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">124</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">63</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">101</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">130</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">130</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">225</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">88</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">88</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP), severe aplastic anemia (SAA)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">39</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-83</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">140</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-49</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-50</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">179</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-64</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-65</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-14</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">154</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">160</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">30</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-81</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">112</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-32</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-34</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">142</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-57</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-58</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">126</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-27</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-30</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">126</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-27</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-30</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:top"><td colspan="5" style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 brands total</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">5 333</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-7</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">6 448</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">10</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">8</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">11 781</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">2</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:top"><td colspan="5" style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">621</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">14</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 006</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 627</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:top"><td colspan="5" style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">5 954</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-5</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">8 454</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">8</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">14 408</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">3</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:top"><td colspan="23" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹ Net sales to third parties by location of customer<b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">² Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 43.<b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">³ Net sales to third parties reflect <i>Xolair</i> sales for all indications.<b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">⁴ Net sales to third parties reflect <i>Fabhalta</i> sales for all indications.<b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">⁵ Mainly due to change in revenue deductions<b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful<b></b></div></td></tr></table></div></div></div></div><div><div><div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net sales to third parties¹ of the top 20 brands in 2026</span></div><div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000; "><b>First half</b></div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td align="center" colspan="3" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> US</div></td><td></td><td align="center" colspan="5" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of world</div></td><td></td><td align="center" colspan="5" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total</div></td><td></td></tr><tr><td style=";height:3;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="5" style=";height:3;"></td><td style=";height:1;"></td><td colspan="5" style=";height:3;"></td><td style=";height:1;"></td></tr><tr><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td colspan="3" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td><td colspan="5" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td><td colspan="5" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td></tr><tr><td style=";height:3;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="5" style=";height:3;"></td><td style=";height:1;"></td><td colspan="5" style=";height:3;"></td><td style=";height:1;"></td></tr><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brands</div></td><td></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by therapeutic area or established brands</div></td><td></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Key indications</div></td><td></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change USD/cc<sup style="white-space: nowrap">2</sup></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change USD</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change cc<sup style="white-space: nowrap">2</sup></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change USD</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change cc<sup style="white-space: nowrap">2</sup></div></td><td></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;width:12%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div></td><td style="text-align:right;width:1%;"></td><td style=";width:12%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology </div></td><td style="text-align:right;width:1%;"></td><td style=";width:12%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA), hidradenitis suppurativa (HS)</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 839</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 551</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3 390</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2- metastatic breast cancer and early breast cancer</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 970</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">47</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 241</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">56</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">49</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3 211</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">51</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">48</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing forms of multiple sclerosis (MS)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 666</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">28</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">922</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">36</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">31</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 588</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">31</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">29</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, renal and metabolic</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure, hypertension</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">70</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-97</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 416</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 486</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-46</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-48</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Pluvicto</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PSMA-positive mCRPC patients post-ARPI, pre- and post-Taxane</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">999</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">55</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">294</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">63</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">55</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 293</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">57</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">55</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF), polycythemia vera (PV), graft-versus-host disease (GvHD)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 133</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">12</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 133</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">12</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Tafinlar</i> + <i>Mekinist</i></div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic and adjuvant melanoma, advanced non-small cell lung cancer (NSCLC), tumor agnostic with BRAF mutation indication, pediatric low grade glioma (pLGG)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">367</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-19</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">707</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 074</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-5</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-7</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">561</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">17</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">464</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">11</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 025</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">14</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">13</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Scemblix</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP); Ph+ CML in CP with the T315I mutation</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">655</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">90</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">340</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">78</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">76</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">995</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">86</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">85</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Leqvio</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, renal and metabolic </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Atherosclerotic cardiovascular disease (ASCVD)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">380</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">43</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">552</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">90</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">83</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">932</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">68</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">64</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap"> 3</sup></div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps, food allergy (FA)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">730</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-19</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-22</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">730</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-19</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-22</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Zolgensma</i> Group</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy (SMA)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">269</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">20</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">398</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-6</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">667</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Sandostatin</i> Group</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors, acromegaly</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">339</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-12</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">250</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">589</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-5</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-7</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GEP-NETs gastroenteropancreatic neuroendocrine tumors</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">314</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">122</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">436</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-33</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">392</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">394</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Fabhalta<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Paroxysmal Nocturnal Hemoglobinuria (PNH), IgA Nephropathy (IgAN), Adult C3 Glomerulopathy (C3G)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">223</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">74</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">171</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">134</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">128</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">394</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">96</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">94</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP), severe aplastic anemia (SAA)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">64</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-88</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">299</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-44</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-46</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">363</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-65</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-66</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">16</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-20</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">294</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">310</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-2</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">58</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-84</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">239</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-31</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-34</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">297</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-58</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-59</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">230</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-36</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-40</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">230</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-36</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-40</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:top"><td colspan="5" style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 brands total</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">9 792</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-10</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">12 745</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">11</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">22 537</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-2</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:top"><td colspan="5" style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 121</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3 863</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-3</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4 984</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-2</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:top"><td colspan="5" style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">10 913</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-9</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">16 608</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">8</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">4</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">27 521</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-2</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:top"><td colspan="23" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹ Net sales to third parties by location of customer<b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">² Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 43.<b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">³ Net sales to third parties reflect <i>Xolair</i> sales for all indications.<b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">⁴ Net sales to third parties reflect <i>Fabhalta</i> sales for all indications.<b></b></div></td></tr></table></div></div></div><div><div></div></div></div><div><div><div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Other revenues </span></div></div></div><div><div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025</div></td><td></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit sharing income</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">456</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">356</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">788</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">613</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income<sup style="white-space: nowrap"> 1</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">27</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">318</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">53</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">326</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">35</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">18</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">89</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other<sup style="white-space: nowrap"> 2</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">55</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">73</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">95</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">141</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">543</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">782</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">954</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">1 169</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:bottom"><td colspan="10" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><b></b></div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹<span> In the second quarter and first half of 2025, royalty income includes a royalty settlement of USD 0.3 billion.</span></div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">² Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties.</div></td></tr></table></div></div></div></div> <div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net sales to third parties by region¹</span></div><div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000; "><b>Second quarter</b></div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2026<br/> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2025<br/> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change<br/> USD</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change<br/> cc<sup style="white-space: nowrap">2</sup></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2026<br/> % of total</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2025<br/> % of total</div></td><td></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   US</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5 954</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">6 249</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-5</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-5</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">41</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">44</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Europe</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4 441</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">4 170</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">31</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">30</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Asia/Africa/Australasia</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3 018</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">2 713</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">11</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">11</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">21</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">19</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Canada and Latin America</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">995</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">922</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">7</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">14 408</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">14 054</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">3</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">100</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">100</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">   Of which in established markets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10 536</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">10 537</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">73</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">75</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">   Of which in emerging growth markets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3 872</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">3 517</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">27</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">25</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td colspan="14"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹ Net sales to third parties by location of customer. Emerging growth markets comprise all markets other than the established markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. Novartis definition of Western Europe includes Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Luxembourg, Malta, The Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.</div></td></tr><tr style="vertical-align:bottom"><td colspan="14"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">² Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 43.</div></td></tr></table></div><div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000; "><b>First half</b></div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026<br/> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025<br/> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change<br/> USD</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change<br/> cc<sup style="white-space: nowrap">2</sup></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026<br/> % of total</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025<br/> % of total</div></td><td></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   US</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10 913</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">11 961</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-9</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-9</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">40</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:7%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">44</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Europe</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8 627</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">8 075</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">31</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">30</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Asia/Africa/Australasia</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6 038</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">5 485</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">22</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">20</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Canada and Latin America</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 943</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 766</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">6</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">27 521</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">27 287</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-2</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">100</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">100</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">   Of which in established markets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">19 798</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">20 206</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-2</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-4</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">72</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">74</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">   Of which in emerging growth markets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7 723</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">7 081</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">28</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">26</div></td><td style="text-align:right"></td></tr><tr><td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td colspan="14" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="14"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹ Net sales to third parties by location of customer. Emerging growth markets comprise all markets other than the established markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. Novartis definition of Western Europe includes Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Luxembourg, Malta, The Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.</div></td></tr><tr style="vertical-align:bottom"><td colspan="14"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">² Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 43.</div></td></tr></table></div></div> 5954000000 6249000000 -0.05 -0.05 0.41 0.44 4441000000 4170000000 0.06 0.04 0.31 0.30 3018000000 2713000000 0.11 0.11 0.21 0.19 995000000 922000000 0.08 0.03 0.07 0.07 14408000000 14054000000 0.03 0.01 1 1 10536000000 10537000000 0 0 0.73 0.75 3872000000 3517000000 0.10 0.06 0.27 0.25 10913000000 11961000000 -0.09 -0.09 0.40 0.44 8627000000 8075000000 0.07 0.01 0.31 0.30 6038000000 5485000000 0.10 0.08 0.22 0.20 1943000000 1766000000 0.10 0.05 0.07 0.06 27521000000 27287000000 0.01 -0.02 1 1 19798000000 20206000000 -0.02 -0.04 0.72 0.74 7723000000 7081000000 0.09 0.04 0.28 0.26 <div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net sales to third parties by core therapeutic area and established brands </span></div><div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000; "><b>Second quarter</b></div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change</div></td><td></td></tr><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> cc<sup style="white-space: nowrap">1</sup></div></td><td></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular, renal and metabolic</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 181</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">2 357</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-50</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-51</span></div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Leqvio</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">480</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">298</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">61</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">59</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Vanrafia</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">27</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cardiovascular, renal and metabolic</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1 688</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">2 655</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-36</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-37</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 824</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 629</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">12</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">550</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">477</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap"> 2</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">342</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">443</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-23</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-25</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Rhapsido</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">64</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total immunology</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">2 780</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">2 549</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">8</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 424</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 077</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">32</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">32</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Zolgensma</i> Group</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">365</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">297</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">23</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">20</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">88</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">83</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total neuroscience</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1 877</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">1 457</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">29</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">28</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Oncology</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 695</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 177</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">44</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">43</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Pluvicto</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">651</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">454</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">43</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">43</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">576</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">524</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Tafinlar</i> + <i>Mekinist</i></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">581</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">573</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Scemblix</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">562</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">298</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">89</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">89</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">225</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">207</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Fabhalta<sup style="white-space: nowrap"> 3</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">225</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">120</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">88</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">88</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total oncology<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">4 515</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">3 353</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">35</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">34</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established brands</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Sandostatin</i> Group</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">302</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">303</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-1</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">191</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">191</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-3</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">179</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">502</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-64</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-65</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">160</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">154</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">142</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">327</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-57</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-58</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">126</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">173</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-27</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-30</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Myfortic<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">105</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">102</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray/Vijoice<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">123</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">111</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">11</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">88</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">99</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-11</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-10</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contract manufacturing</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">472</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">276</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">71</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">68</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 660</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 802</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-8</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-9</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total established brands<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">3 548</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">4 040</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-12</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-14</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total net sales to third parties</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">14 408</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">14 054</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">3</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td colspan="10" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹ Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 43.</div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">² Net sales to third parties reflect <i>Xolair</i> sales for all indications.<b></b><b></b><b></b><b></b><b></b><b></b><b></b></div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">³ Net sales to third parties reflect <i>Fabhalta</i> sales for all indications.<b></b><b></b><b></b><b></b><b></b><b></b><b></b></div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">⁴ Reclassified to conform with 2026 presentation of brands by therapeutic area and established brands.</div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="10" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div></td></tr></table></div></div><div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net sales to third parties by core therapeutic area and established brands </span></div><div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000; "><b>First half</b></div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change</div></td><td></td></tr><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> cc<sup style="white-space: nowrap">1</sup></div></td><td></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular, renal and metabolic</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 486</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">4 618</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-46</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-48</span></div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Leqvio</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">932</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">555</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">68</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">64</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Vanrafia</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">43</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cardiovascular, renal and metabolic</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">3 461</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">5 173</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-33</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-35</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3 390</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">3 163</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 025</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">896</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">14</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">13</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap"> 2</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">730</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">899</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-19</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-22</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Rhapsido</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">101</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total immunology</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">5 246</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">4 958</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">3</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 588</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 976</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">31</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">29</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Zolgensma</i> Group</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">667</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">624</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">183</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">159</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total neuroscience</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">3 438</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">2 759</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">25</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">22</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Oncology</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3 211</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">2 133</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">51</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">48</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Pluvicto</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 293</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">825</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">57</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">55</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 133</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 016</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">12</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Tafinlar</i> + <i>Mekinist</i></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 074</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 125</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-5</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-7</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Scemblix</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">995</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">536</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">86</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">85</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">436</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">400</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Fabhalta<sup style="white-space: nowrap"> 3</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">394</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">201</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">96</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">94</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total oncology<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">8 536</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">6 236</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">37</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">34</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established brands</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Sandostatin</i> Group</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">589</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">620</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-5</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-7</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">394</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">370</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">363</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 048</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-65</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-66</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">310</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">304</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-2</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">297</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">704</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-58</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-59</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">230</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">362</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-36</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-40</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Myfortic<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">216</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">201</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray/Vijoice<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">204</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">211</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-3</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-4</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">169</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">199</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-15</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-16</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contract manufacturing</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">824</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">619</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">33</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">27</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3 244</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">3 523</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-8</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-11</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total established brands<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">6 840</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">8 161</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-16</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-19</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total net sales to third parties</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">27 521</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">27 287</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-2</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td colspan="10" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹ Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 43.</div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">² Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">³ Net sales to third parties reflect <i>Fabhalta</i> sales for all indications.</div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">⁴ Reclassified to conform with 2026 presentation of brands by therapeutic area and established brands.</div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="10" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div></td></tr></table></div></div> 1181000000 2357000000 -0.50 -0.51 480000000 298000000 0.61 0.59 27000000 1688000000 2655000000 -0.36 -0.37 1824000000 1629000000 0.12 0.10 550000000 477000000 0.15 0.15 342000000 443000000 -0.23 -0.25 64000000 2780000000 2549000000 0.09 0.08 1424000000 1077000000 0.32 0.32 365000000 297000000 0.23 0.20 88000000 83000000 0.06 0.03 1877000000 1457000000 0.29 0.28 1695000000 1177000000 0.44 0.43 651000000 454000000 0.43 0.43 576000000 524000000 0.10 0.08 581000000 573000000 0.01 0 562000000 298000000 0.89 0.89 225000000 207000000 0.09 0.08 225000000 120000000 0.88 0.88 4515000000 3353000000 0.35 0.34 302000000 303000000 0 -0.01 191000000 191000000 0 -0.03 179000000 502000000 -0.64 -0.65 160000000 154000000 0.04 0.02 142000000 327000000 -0.57 -0.58 126000000 173000000 -0.27 -0.30 105000000 102000000 0.03 0 123000000 111000000 0.11 0.10 88000000 99000000 -0.11 -0.10 472000000 276000000 0.71 0.68 1660000000 1802000000 -0.08 -0.09 3548000000 4040000000 -0.12 -0.14 14408000000 14054000000 0.03 0.01 2486000000 4618000000 -0.46 -0.48 932000000 555000000 0.68 0.64 43000000 3461000000 5173000000 -0.33 -0.35 3390000000 3163000000 0.07 0.05 1025000000 896000000 0.14 0.13 730000000 899000000 -0.19 -0.22 101000000 5246000000 4958000000 0.06 0.03 2588000000 1976000000 0.31 0.29 667000000 624000000 0.07 0.03 183000000 159000000 0.15 0.08 3438000000 2759000000 0.25 0.22 3211000000 2133000000 0.51 0.48 1293000000 825000000 0.57 0.55 1133000000 1016000000 0.12 0.06 1074000000 1125000000 -0.05 -0.07 995000000 536000000 0.86 0.85 436000000 400000000 0.09 0.08 394000000 201000000 0.96 0.94 8536000000 6236000000 0.37 0.34 589000000 620000000 -0.05 -0.07 394000000 370000000 0.06 0.02 363000000 1048000000 -0.65 -0.66 310000000 304000000 0.02 -0.02 297000000 704000000 -0.58 -0.59 230000000 362000000 -0.36 -0.40 216000000 201000000 0.07 0.04 204000000 211000000 -0.03 -0.04 169000000 199000000 -0.15 -0.16 824000000 619000000 0.33 0.27 3244000000 3523000000 -0.08 -0.11 6840000000 8161000000 -0.16 -0.19 27521000000 27287000000 0.01 -0.02 <div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net sales to third parties¹ of the top 20 brands in 2026</span></div><div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000; "><b>Second quarter</b></div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td align="center" colspan="3" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> US</div></td><td></td><td align="center" colspan="5" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of world</div></td><td></td><td align="center" colspan="5" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total</div></td><td></td></tr><tr><td style=";height:3;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="5" style=";height:3;"></td><td style=";height:1;"></td><td colspan="5" style=";height:3;"></td><td style=";height:1;"></td></tr><tr><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td colspan="3" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td><td colspan="5" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td><td colspan="5" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td></tr><tr><td style=";height:3;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="5" style=";height:3;"></td><td style=";height:1;"></td><td colspan="5" style=";height:3;"></td><td style=";height:1;"></td></tr><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brands</div></td><td></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by therapeutic area or established brands</div></td><td></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Key indications</div></td><td></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change USD/cc<sup style="white-space: nowrap">2</sup></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change USD</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change cc<sup style="white-space: nowrap">2</sup></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change USD</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change cc<sup style="white-space: nowrap">2</sup></div></td><td></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;width:12%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div></td><td style="text-align:right;width:1%;"></td><td style=";width:12%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology </div></td><td style="text-align:right;width:1%;"></td><td style=";width:12%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA), hidradenitis suppurativa (HS)</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 069</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">16</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">755</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 824</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">12</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2- metastatic breast cancer and early breast cancer</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 045</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">39</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">650</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">52</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">49</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 695</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">44</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">43</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing forms of multiple sclerosis (MS)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">942</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">32</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">482</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">32</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">30</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 424</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">32</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">32</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, renal and metabolic</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure, hypertension</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-2</span><sup style="white-space: nowrap"> 5 </sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm </div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 183</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 181</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-50</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-51</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Pluvicto</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PSMA-positive mCRPC patients post-ARPI, pre- and post-Taxane</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">493</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">38</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">158</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">65</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">62</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">651</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">43</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">43</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF), polycythemia vera (PV), graft-versus-host disease (GvHD)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">576</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">576</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Tafinlar</i> + <i>Mekinist</i></div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic and adjuvant melanoma, advanced non-small cell lung cancer (NSCLC), tumor agnostic with BRAF mutation indication, pediatric low grade glioma (pLGG)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">197</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-20</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">384</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">17</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">581</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">315</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">21</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">235</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">550</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Scemblix</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP); Ph+ CML in CP with the T315I mutation</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">369</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">93</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">193</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">80</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">82</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">562</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">89</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">89</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Leqvio</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, renal and metabolic </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Atherosclerotic cardiovascular disease (ASCVD)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">214</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">55</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">266</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">66</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">63</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">480</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">61</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">59</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap"> 3</sup></div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps, food allergy (FA)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">342</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-23</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-25</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">342</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-23</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-25</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Zolgensma</i> Group</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy (SMA)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">152</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">58</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">213</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">365</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">23</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">20</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Sandostatin</i> Group</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors, acromegaly</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">177</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-5</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">125</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">302</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-1</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GEP-NETs gastroenteropancreatic neuroendocrine tumors</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">163</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">62</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">225</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">191</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-3</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">191</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-3</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Fabhalta<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Paroxysmal Nocturnal Hemoglobinuria (PNH), IgA Nephropathy (IgAN), Adult C3 Glomerulopathy (C3G)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">124</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">63</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">101</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">130</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">130</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">225</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">88</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">88</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP), severe aplastic anemia (SAA)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">39</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-83</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">140</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-49</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-50</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">179</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-64</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-65</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-14</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">154</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">160</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">30</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-81</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">112</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-32</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-34</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">142</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-57</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-58</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">126</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-27</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-30</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">126</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-27</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-30</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:top"><td colspan="5" style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 brands total</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">5 333</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-7</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">6 448</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">10</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">8</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">11 781</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">2</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:top"><td colspan="5" style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">621</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">14</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 006</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 627</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:top"><td colspan="5" style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">5 954</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-5</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">8 454</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">8</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">14 408</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">3</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:top"><td colspan="23" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹ Net sales to third parties by location of customer<b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">² Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 43.<b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">³ Net sales to third parties reflect <i>Xolair</i> sales for all indications.<b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">⁴ Net sales to third parties reflect <i>Fabhalta</i> sales for all indications.<b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">⁵ Mainly due to change in revenue deductions<b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"><b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful<b></b></div></td></tr></table></div></div><div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net sales to third parties¹ of the top 20 brands in 2026</span></div><div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000; "><b>First half</b></div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td><td></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td align="center" colspan="3" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> US</div></td><td></td><td align="center" colspan="5" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of world</div></td><td></td><td align="center" colspan="5" style="text-align:center;height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total</div></td><td></td></tr><tr><td style=";height:3;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="5" style=";height:3;"></td><td style=";height:1;"></td><td colspan="5" style=";height:3;"></td><td style=";height:1;"></td></tr><tr><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td colspan="3" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td><td colspan="5" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td><td colspan="5" style="border-bottom: solid #000000 1px;"></td><td style=";height:1;"></td></tr><tr><td style=";height:3;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td style=";height:1;"></td><td colspan="3" style=";height:3;"></td><td style=";height:1;"></td><td colspan="5" style=";height:3;"></td><td style=";height:1;"></td><td colspan="5" style=";height:3;"></td><td style=";height:1;"></td></tr><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brands</div></td><td></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by therapeutic area or established brands</div></td><td></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Key indications</div></td><td></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change USD/cc<sup style="white-space: nowrap">2</sup></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change USD</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change cc<sup style="white-space: nowrap">2</sup></div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD m</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change USD</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change cc<sup style="white-space: nowrap">2</sup></div></td><td></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;width:12%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div></td><td style="text-align:right;width:1%;"></td><td style=";width:12%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology </div></td><td style="text-align:right;width:1%;"></td><td style=";width:12%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA), hidradenitis suppurativa (HS)</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 839</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 551</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3 390</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:4%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2- metastatic breast cancer and early breast cancer</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 970</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">47</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 241</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">56</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">49</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3 211</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">51</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">48</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing forms of multiple sclerosis (MS)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 666</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">28</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">922</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">36</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">31</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 588</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">31</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">29</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, renal and metabolic</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure, hypertension</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">70</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-97</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 416</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 486</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-46</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-48</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Pluvicto</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PSMA-positive mCRPC patients post-ARPI, pre- and post-Taxane</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">999</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">55</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">294</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">63</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">55</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 293</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">57</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">55</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF), polycythemia vera (PV), graft-versus-host disease (GvHD)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 133</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">12</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 133</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">12</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Tafinlar</i> + <i>Mekinist</i></div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic and adjuvant melanoma, advanced non-small cell lung cancer (NSCLC), tumor agnostic with BRAF mutation indication, pediatric low grade glioma (pLGG)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">367</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-19</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">707</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 074</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-5</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-7</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">561</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">17</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">464</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">11</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 025</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">14</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">13</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Scemblix</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP); Ph+ CML in CP with the T315I mutation</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">655</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">90</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">340</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">78</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">76</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">995</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">86</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">85</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Leqvio</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular, renal and metabolic </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Atherosclerotic cardiovascular disease (ASCVD)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">380</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">43</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">552</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">90</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">83</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">932</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">68</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">64</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap"> 3</sup></div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps, food allergy (FA)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">730</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-19</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-22</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">730</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-19</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-22</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Zolgensma</i> Group</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy (SMA)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">269</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">20</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">398</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-6</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">667</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Sandostatin</i> Group</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors, acromegaly</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">339</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-12</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">250</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">589</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-5</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-7</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GEP-NETs gastroenteropancreatic neuroendocrine tumors</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">314</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">122</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">436</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">9</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">8</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exforge</i> Group</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-33</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">392</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">7</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">394</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Fabhalta<sup style="white-space: nowrap"> 4</sup></div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Paroxysmal Nocturnal Hemoglobinuria (PNH), IgA Nephropathy (IgAN), Adult C3 Glomerulopathy (C3G)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">223</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">74</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">171</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">134</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">128</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">394</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">96</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">94</div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP), severe aplastic anemia (SAA)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">64</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-88</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">299</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-44</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-46</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">363</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-65</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-66</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Diovan</i> Group</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">16</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-20</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">294</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">310</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-2</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">58</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-84</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">239</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-31</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-34</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">297</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-58</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-59</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:top"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established brands </div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO)</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">230</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-36</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-40</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">230</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-36</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-40</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:top"><td colspan="5" style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 brands total</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">9 792</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-10</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">12 745</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">11</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">6</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">22 537</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-2</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:top"><td colspan="5" style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 121</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3 863</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-3</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4 984</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-2</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:top"><td colspan="5" style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">10 913</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-9</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">16 608</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">8</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">4</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">27 521</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">1</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"><span>-2</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="23" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:top"><td colspan="23" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹ Net sales to third parties by location of customer<b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">² Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 43.<b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">³ Net sales to third parties reflect <i>Xolair</i> sales for all indications.<b></b></div></td></tr><tr style="vertical-align:top"><td colspan="23"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">⁴ Net sales to third parties reflect <i>Fabhalta</i> sales for all indications.<b></b></div></td></tr></table></div></div> 1069000000 0.16 755000000 0.07 0.03 1824000000 0.12 0.10 1045000000 0.39 650000000 0.52 0.49 1695000000 0.44 0.43 942000000 0.32 482000000 0.32 0.30 1424000000 0.32 0.32 -2000000 1183000000 0.04 0.03 1181000000 -0.50 -0.51 493000000 0.38 158000000 0.65 0.62 651000000 0.43 0.43 576000000 0.10 0.08 576000000 0.10 0.08 197000000 -0.20 384000000 0.17 0.15 581000000 0.01 0 315000000 0.21 235000000 0.08 0.08 550000000 0.15 0.15 369000000 0.93 193000000 0.80 0.82 562000000 0.89 0.89 214000000 0.55 266000000 0.66 0.63 480000000 0.61 0.59 342000000 -0.23 -0.25 342000000 -0.23 -0.25 152000000 0.58 213000000 0.06 0.02 365000000 0.23 0.20 177000000 -0.05 125000000 0.08 0.07 302000000 0 -0.01 163000000 0.09 62000000 0.09 0.06 225000000 0.09 0.08 191000000 0.01 -0.03 191000000 0 -0.03 124000000 0.63 101000000 1.30 1.30 225000000 0.88 0.88 39000000 -0.83 140000000 -0.49 -0.50 179000000 -0.64 -0.65 6000000 -0.14 154000000 0.05 0.03 160000000 0.04 0.02 30000000 -0.81 112000000 -0.32 -0.34 142000000 -0.57 -0.58 126000000 -0.27 -0.30 126000000 -0.27 -0.30 5333000000 -0.07 6448000000 0.10 0.08 11781000000 0.02 0.01 621000000 0.14 2006000000 0.04 0.02 2627000000 0.06 0.05 5954000000 -0.05 8454000000 0.08 0.06 14408000000 0.03 0.01 1839000000 0.06 1551000000 0.09 0.03 3390000000 0.07 0.05 1970000000 0.47 1241000000 0.56 0.49 3211000000 0.51 0.48 1666000000 0.28 922000000 0.36 0.31 2588000000 0.31 0.29 70000000 -0.97 2416000000 0.09 0.05 2486000000 -0.46 -0.48 999000000 0.55 294000000 0.63 0.55 1293000000 0.57 0.55 1133000000 0.12 0.06 1133000000 0.12 0.06 367000000 -0.19 707000000 0.05 0.01 1074000000 -0.05 -0.07 561000000 0.17 464000000 0.11 0.07 1025000000 0.14 0.13 655000000 0.90 340000000 0.78 0.76 995000000 0.86 0.85 380000000 0.43 552000000 0.90 0.83 932000000 0.68 0.64 730000000 -0.19 -0.22 730000000 -0.19 -0.22 269000000 0.20 398000000 0 -0.06 667000000 0.07 0.03 339000000 -0.12 250000000 0.06 0.02 589000000 -0.05 -0.07 314000000 0.09 122000000 0.10 0.05 436000000 0.09 0.08 2000000 -0.33 392000000 0.07 0.02 394000000 0.06 0.02 223000000 0.74 171000000 1.34 1.28 394000000 0.96 0.94 64000000 -0.88 299000000 -0.44 -0.46 363000000 -0.65 -0.66 16000000 -0.20 294000000 0.04 0 310000000 0.02 -0.02 58000000 -0.84 239000000 -0.31 -0.34 297000000 -0.58 -0.59 230000000 -0.36 -0.40 230000000 -0.36 -0.40 9792000000 -0.10 12745000000 0.11 0.06 22537000000 0.01 -0.02 1121000000 0.03 3863000000 0.01 -0.03 4984000000 0.01 -0.02 10913000000 -0.09 16608000000 0.08 0.04 27521000000 0.01 -0.02 <div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025</div></td><td></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit sharing income</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">456</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">356</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">788</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">613</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income<sup style="white-space: nowrap"> 1</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">27</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">318</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">53</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">326</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">35</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">18</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">89</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other<sup style="white-space: nowrap"> 2</sup></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">55</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">73</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">95</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">141</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">543</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">782</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">954</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">1 169</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:bottom"><td colspan="10" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><b></b></div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">¹<span> In the second quarter and first half of 2025, royalty income includes a royalty settlement of USD 0.3 billion.</span></div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">² Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties.</div></td></tr></table></div></div> 456000000 356000000 788000000 613000000 27000000 318000000 53000000 326000000 5000000 35000000 18000000 89000000 55000000 73000000 95000000 141000000 543000000 782000000 954000000 1169000000 300000000 300000000 <div><div id="anchorId00233558"></div><div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">10. Other interim disclosures</div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Property, plant and equipment, right-of-use assets and intangible assets </span></div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">The following table shows additional disclosures related to property, plant and equipment, right-of-use assets and intangible assets:</div><div><div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025</div></td><td></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment impairment charges</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-4</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-39</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-6</span></div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment depreciation charge</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-261</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-241</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-520</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-456</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets impairment charges</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-1</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-1</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets depreciation charge</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-77</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-68</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-150</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-133</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets impairment charges</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-199</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-92</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-199</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-94</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets amortization charge</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-862</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-851</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-1 719</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-1 721</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td colspan="10" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"></div></td></tr></table></div></div></div><div><div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">In the first half of 2026 and 2025, there were no reversals of impairment charges on property, plant and equipment, right-of-use assets and intangible assets.</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The following table shows the additions to property, plant and equipment, right-of-use assets and intangible assets other than goodwill, excluding the impacts of the first half of 2026 business combinations and acquisitions applying the optional concentration test, which are disclosed in Note 3:</div></div></div><div><div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025</div></td><td></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to property, plant and equipment</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">335</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">349</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">610</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">559</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to right-of-use assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">102</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">81</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">151</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">137</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to intangible assets other than goodwill</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">408</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">198</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">852</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 377</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr></table></div></div></div><div><div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Financial debts </span></div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">The acquisition of Avidity Biosciences, Inc., completed on February 27, 2026, was initially financed through a USD 11.0 billion bridge loan with an interest rate based on compounded Secured Overnight Financing Rate (SOFR). The bridge loan was fully repaid on March 18, 2026, using the proceeds from the straight and floating rate bonds issued in the first quarter of 2026. </div></div></div></div><div><div><div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The following table provides a breakdown of straight and floating rate bonds issued in the first half of 2026:</div></div></div><div><div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/>Coupon</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/><br/> Currency</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Notional <br/> amount<br/> (millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/> Issuance <br/> year</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/> Maturity <br/> year</div></td><td></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/><br/> Issuer</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/><br/> Issue price</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br/> USD<br/> millions</div></td><td></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">SOFR + <span>0.65%</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USD</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">500</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2029</div></td><td style="text-align:right;width:1%;"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation, New York, United States</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>100.000%</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">499</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>4.100%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USD</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 250</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2029</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation, New York, United States</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>99.883%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 247</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>4.400%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USD</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 750</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2031</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation, New York, United States</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>99.960%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 746</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>4.600%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USD</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 000</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2033</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation, New York, United States</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>99.574%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 986</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>4.900%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USD</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 250</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2036</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation, New York, United States</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>99.719%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 237</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>5.600%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USD</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 000</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2046</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation, New York, United States</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>99.536%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">990</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>5.700%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USD</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 250</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2056</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation, New York, United States</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>99.120%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 216</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>3.100%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">EUR</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">600</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2032</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance S.A., Luxembourg, Luxembourg</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>99.525%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">679</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>3.500%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">EUR</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">600</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2035</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance S.A., Luxembourg, Luxembourg</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>99.757%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">681</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>4.000%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">EUR</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">500</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2041</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance S.A., Luxembourg, Luxembourg</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>99.833%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">568</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total straight and floating rate bonds issued in the first half of 2026</div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">12 849</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total straight and floating rate bonds, June 30, 2026</div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">40 542</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total straight and floating rate bonds, December 31, 2025</div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">27 929</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td></td><td></td><td></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="16" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr></table></div></div></div><div><div><div><span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net investment hedge designation</span></div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">In addition to the existing hedges as of December 31, 2025, the Company has further designated the newly issued Euro-denominated straight bonds maturing 2032 (EUR 600 million), 2035 (EUR 600 million) and 2041 (EUR 500 million) as hedges of the translation risk arising on certain of these net investments in foreign operations with a Euro functional currency. As of June 30, 2026, long-term financial debt with a carrying amount of EUR 5.0 billion (USD 5.7 billion, December 31, 2025: USD 3.9 billion), have been designated as hedge instruments. The hedges remained effective since inception, and no amount was recognized in the consolidated income statement in 2025 and 2026 year-to-date.</div><div style="padding-bottom: 10px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"><span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Commitments </span></div><div><span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Research and development commitments</span></div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">The Company has entered into long-term research and development agreements related to intangible assets with various third parties. The Company has also entered into acquisition agreements related to intangible assets with third parties that were accounted for as assets separately acquired by electing to apply the optional concentration test. These agreements may provide for potential milestone payments by Novartis, which are dependent on successful achievement of specified clinical development, regulatory approval, or sales milestones, or other conditions specified in the agreements.</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">As of June 30, 2026, the amount and estimated timing of the Company’s commitments to make payments under those agreements, which are shown without risk adjustment and on an undiscounted basis, were as follows:</div></div></div><div><div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/>(USD millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br/> 2026</div></td><td></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:20%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">263</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 888</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2028</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">957</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2029</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 494</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2030</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 095</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2031</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 213</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Thereafter</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">12 813</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">19 723</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 3px;"></td></tr></table></div></div></div><div><div><div><span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other commitments</span></div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">The Company has entered into various purchase commitments for services and materials as well as for equipment in the ordinary course of business. These commitments are generally entered into at current market prices and reflect normal business operations. </div><div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">The Company routinely acquires interests in intellectual property focused on key disease areas and indications that the Company expects to be growth drivers in the future.</div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-indent:20.0pt;">Pending acquisition commitment to acquire Myricx Bio – On July 5, 2026, Novartis entered into a stock purchase agreement to acquire Myricx Bio, a privately held UK-based biotechnology company developing a new class of antibody-drug conjugates (ADCs), using N-myristoyltransferase inhibitor (NMTi) payloads. Under the terms of the agreement Novartis will make a payment of USD 1.1 billion at closing and up to USD 0.4 billion in additional payments contingent upon the achievement of specified milestones. The transaction is expected to close in the second half of 2026, subject to satisfaction or waiver of customary closing conditions, including regulatory approval. </div></div></div></div> <div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025</div></td><td></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment impairment charges</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-4</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-39</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-6</span></div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment depreciation charge</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-261</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-241</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-520</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-456</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets impairment charges</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-1</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-1</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets depreciation charge</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-77</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-68</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-150</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-133</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets impairment charges</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-199</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-92</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-199</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-94</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets amortization charge</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-862</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-851</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>-1 719</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"><span>-1 721</span></div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td colspan="10" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="10"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"></div></td></tr></table></div></div> 4000000 39000000 6000000 261000000 241000000 520000000 456000000 1000000 1000000 77000000 68000000 150000000 133000000 199000000 92000000 199000000 94000000 862000000 851000000 1719000000 1721000000 0 0 0 0 0 0 <div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Q2 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Q2 2025</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> H1 2026</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> H1 2025</div></td><td></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to property, plant and equipment</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">335</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">349</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">610</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:9%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">559</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to right-of-use assets</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">102</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">81</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">151</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">137</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to intangible assets other than goodwill</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">408</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">198</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">852</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">1 377</div></td><td style="text-align:right"></td></tr><tr><td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td></tr></table></div></div> 335000000 349000000 610000000 559000000 102000000 81000000 151000000 137000000 408000000 198000000 852000000 1377000000 11000000000.0 <div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/>Coupon</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/><br/> Currency</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Notional <br/> amount<br/> (millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/> Issuance <br/> year</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/> Maturity <br/> year</div></td><td></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/><br/> Issuer</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/><br/> Issue price</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"><br/> USD<br/> millions</div></td><td></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">SOFR + <span>0.65%</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USD</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">500</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2029</div></td><td style="text-align:right;width:1%;"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation, New York, United States</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>100.000%</span></div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">499</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>4.100%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USD</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 250</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2029</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation, New York, United States</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>99.883%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 247</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>4.400%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USD</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 750</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2031</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation, New York, United States</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>99.960%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 746</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>4.600%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USD</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 000</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2033</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation, New York, United States</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>99.574%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 986</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>4.900%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USD</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 250</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2036</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation, New York, United States</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>99.719%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 237</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>5.600%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USD</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 000</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2046</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation, New York, United States</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>99.536%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">990</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>5.700%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USD</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 250</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2056</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation, New York, United States</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>99.120%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2 216</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>3.100%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">EUR</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">600</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2032</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance S.A., Luxembourg, Luxembourg</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>99.525%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">679</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>3.500%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">EUR</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">600</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2035</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance S.A., Luxembourg, Luxembourg</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>99.757%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">681</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>4.000%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">EUR</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">500</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2041</div></td><td style="text-align:right"></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance S.A., Luxembourg, Luxembourg</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><span>99.833%</span></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">568</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total straight and floating rate bonds issued in the first half of 2026</div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">12 849</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total straight and floating rate bonds, June 30, 2026</div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">40 542</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total straight and floating rate bonds, December 31, 2025</div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">27 929</div></td><td style="text-align:right"></td></tr><tr><td colspan="16" style="border-bottom: solid #000000 3px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:10px;"><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td></td><td></td><td></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td><td><div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div></td></tr><tr style="vertical-align:bottom"><td colspan="16" style=";height:10px;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div></td></tr></table></div></div> SOFR 0.65 USD 500000000 2026 2029 Novartis Capital Corporation, New York, United States 1.00000 499000000 0.04100 USD 1250000000 2026 2029 Novartis Capital Corporation, New York, United States 0.99883 1247000000 0.04400 USD 1750000000 2026 2031 Novartis Capital Corporation, New York, United States 0.99960 1746000000 0.04600 USD 2000000000 2026 2033 Novartis Capital Corporation, New York, United States 0.99574 1986000000 0.04900 USD 2250000000 2026 2036 Novartis Capital Corporation, New York, United States 0.99719 2237000000 0.05600 USD 1000000000 2026 2046 Novartis Capital Corporation, New York, United States 0.99536 990000000 0.05700 USD 2250000000 2026 2056 Novartis Capital Corporation, New York, United States 0.99120 2216000000 0.03100 EUR 600000000 2026 2032 Novartis Finance S.A., Luxembourg, Luxembourg 0.99525 679000000 0.03500 EUR 600000000 2026 2035 Novartis Finance S.A., Luxembourg, Luxembourg 0.99757 681000000 0.04000 EUR 500000000 2026 2041 Novartis Finance S.A., Luxembourg, Luxembourg 0.99833 568000000 12849000000 40542000000 27929000000 600000000 600000000 500000000 5000000000.0 5700000000 3900000000 0 0 <div><div style="padding-top:10px; padding-bottom:30px;"><table style="border-collapse:collapse;width:100%;border:0;cellspacing:0;cellpadding:0"><tr style="vertical-align:bottom"><td style=";height:12;"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"><br/>(USD millions)</div></td><td></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Jun 30, <br/> 2026</div></td><td></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div></td><td style="text-align:right;width:1%;"></td><td style="text-align:right;width:20%;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">263</div></td><td style="text-align:right;width:1%;"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 888</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2028</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">957</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2029</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 494</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2030</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 095</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2031</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 213</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Thereafter</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">12 813</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 2px;"></td></tr><tr style="vertical-align:bottom"><td style=";height:16;"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div></td><td style="text-align:right"></td><td style="text-align:right"><div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">19 723</div></td><td style="text-align:right"></td></tr><tr><td colspan="4" style="border-bottom: solid #000000 3px;"></td></tr></table></div></div> 263000000 1888000000 957000000 1494000000 1095000000 1213000000 12813000000 19723000000 1100000000 400000000 <div><div id="anchorId00234599"></div><div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">11. Events subsequent to the June 30, 2026, consolidated balance sheet date</div><div><span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Significant transaction entered into in July 2026 </span></div><div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">On July 5, 2026, the Company entered into a commitment related to a purchase agreement to acquire a company. See Note 10 for further information.</div></div>